

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12390148
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Min; Xiaoyi et al.

Spinal cord stimulation guidance system and method of use

Abstract

A system and method for modeling patient-specific spinal cord stimulation (SCS) is disclosed. The system and method acquire impedance and evoked compound action potential (ECAP) signals from a lead positioned proximate to a spinal cord (SC). The lead includes at least one electrode. The system and method determine a patient-specific anatomical model based on the impedance and ECAP signals, and transform a dorsal column (DC) map template based on a DC boundary of the patient-specific anatomical model. Further, the system and method map the transformed DC map template to the patient-specific anatomical model. The system and method may also include the algorithms to solve extracellular and intracellular domain electrical fields and propagation along neurons. The system and method may also include the user interfaces to collect patient responses and compare with the patient-specific anatomical model as well as using the patient-specific anatomical model for guiding SCS programming.

Inventors:	Min; Xiaoyi (Camarillo, CA), Kent; Alexander (Mountain View, CA)
Applicant:	Pacesetter, Inc. (Sylmar, CA)
Family ID:	1000008763124
Assignee:	Pacesetter, Inc. (Sylmar, CA)
Appl. No.:	18/457629
Filed:	August 29, 2023

Prior Publication Data

Document Identifier	Publication Date
US 20230397875 A1	Dec. 14, 2023

Related U.S. Application Data

continuation parent-doc US 16248144 20190115 US 11786166 child-doc US 18457629
division parent-doc US 14958725 20151203 US 10213148 20190226 child-doc US 16248144

Publication Classification

Int. Cl.: **A61B5/00** (20060101); **A61B5/0536** (20210101); **A61B5/0537** (20210101); **A61B5/388** (20210101); **A61N1/372** (20060101); **A61N1/378** (20060101); **G16H20/40** (20180101); **G16H40/63** (20180101); A61N1/05 (20060101); G16H20/30 (20180101); G16H30/40 (20180101)

U.S. Cl.:

CPC **A61B5/407** (20130101); **A61B5/0536** (20130101); **A61B5/0537** (20130101); **A61B5/388** (20210101); **A61B5/4887** (20130101); **A61B5/6823** (20130101); **A61N1/37247** (20130101); **A61N1/3787** (20130101); **G16H20/40** (20180101); **G16H40/63** (20180101); A61B2562/046 (20130101); A61N1/0553 (20130101); G16H20/30 (20180101); G16H30/40 (20180101)

Field of Classification Search

USPC: None

References Cited**U.S. PATENT DOCUMENTS**

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
7146224	12/2005	King	N/A	N/A
7174215	12/2006	Bradley	N/A	N/A
7216001	12/2006	Hacker et al.	N/A	N/A
8504160	12/2012	Lee et al.	N/A	N/A
8543217	12/2012	Stone et al.	N/A	N/A
9302112	12/2015	Bornzin et al.	N/A	N/A
9381356	12/2015	Parker et al.	N/A	N/A
11786166	12/2022	Min	600/547	A61B 5/4887
2008/0009764	12/2007	Davies	N/A	N/A
2010/0145222	12/2009	Brunnett et al.	N/A	N/A
2010/0152812	12/2009	Flaherty et al.	N/A	N/A
2012/0083709	12/2011	Parker et al.	N/A	N/A
2013/0006324	12/2012	Bradley	N/A	N/A
2014/0148726	12/2013	Wagner	N/A	N/A
2014/0236257	12/2013	Parker et al.	N/A	N/A
2014/0277282	12/2013	Jaax	607/59	A61N 1/36139
2015/0005846	12/2014	Ranu	607/59	A61N 1/36521
2015/0174366	12/2014	Taha	607/46	A61M 25/0043
2015/0224326	12/2014	Toth et al.	N/A	N/A
2016/0121124	12/2015	Johanek	607/62	A61N 1/37247
2016/0166164	12/2015	Obradivuc et al.	N/A	N/A

Primary Examiner: Cheng; Jacqueline

Background/Summary

RELATED APPLICATION DATA (1) This application is a continuation of U.S. application Ser. No. 16/248,144, filed 15 Jan. 2019, which is a divisional of U.S. application Ser. No. 14/958,725, filed 3 Dec. 2015 (now U.S. Pat. No. 10,213,148, issued 26 Feb. 2019), which claims priority from U.S. Application No. 62/088,451 filed 5 Dec. 2014, each entitled “SPINAL CORD STIMULATION GUIDANCE SYSTEM AND METHOD OF USE,” all of which are hereby expressly incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

(1) Embodiments of the present disclosure generally relate to neurostimulation (NS) systems, and more particularly to model-based programming guidance for implantation of spinal cord stimulation (SCS) systems.

(2) NS systems are devices that generate electrical pulses and deliver the pulses to nervous tissue to treat a variety of disorders. For example, SCS has been used to treat chronic and intractable pain. Another example is deep brain stimulation, which has been used to treat movement disorders such as Parkinson's disease and affective disorders such as depression. While a precise understanding of the interaction between the applied electrical energy and the nervous tissue is not fully appreciated, it is known that application of electrical pulses depolarizes neurons and generate propagating action potentials into certain regions or areas of nerve tissue. The propagating action potentials effectively mask certain types of pain transmitted from regions, increase the production of neurotransmitters, or the like. For example, applying electrical energy to the spinal cord associated with regions of the body afflicted with chronic pain can induce “paresthesia” (a subjective sensation of numbness or tingling) in the afflicted bodily regions. Inducing this artificial sensation replaces the feeling of pain in the body areas effectively masking the transmission of non-acute pain sensations to the brain.

(3) Computational modeling of SCS, through coupled three dimensional (3-D) electrical field and nerve fiber kinetic models, can provide a tool for assessing the effectiveness of the SCS and/or a placement of the NS system within the patient. However, current modeling approaches commonly require commercial software packages that involve computationally-intensive steps, such as: obtain magnetic resonance imaging (MRI) of the patient; perform tissue segmentation on the medical images to create a 3-D spinal cord (SC) geometrical model; position the implanted leads within the SC model; specify stimulation contacts on the lead and set boundaries to contact-voltage/current condition; mesh the models; and in two stages solve for the electrical fields and activation regions in the dorsal column (DC) and dorsal root (DR) of the SC; and determine stimulation thresholds and activated dermatomal fiber zones. The process requires multiple software packages and specialized personnel to perform the tasks, which make conventional modeling approach difficult in the clinical setting.

(4) However, some of the SCS systems available are not MRI-compatible, requiring MRI images to be taken prior to implant of the SCS system, and other modalities (e.g., X-rays, computed tomography (CT) scan) are needed to determine SCS lead position after implant. Moreover, detailed SC anatomy is difficult to ascertain with clinical MRI sequences, with dermatomal fiber tracts from such MRI images being difficult to visualize. Further, solving the computational model with the conventional approach is time-consuming, making this difficult to use in the clinical setting during an office visit or SCS implant. A need exists to overcome the shortcomings of

traditional modeling methods.

SUMMARY

(5) In accordance with one embodiment, a method for modeling patient-specific spinal cord stimulation (SCS). The method may include acquiring impedance and evoked compound action potential (ECAP) signals from a lead positioned proximate to a spinal cord (SC). The lead may include at least one electrode. The method may include determining a patient-specific anatomical model based on the impedance and ECAP signals, and transforming a dorsal column (DC) map template based on a DC boundary of the patient-specific anatomical model. Optionally, the method may include acquiring additional impedance and ECAP signals. Each pair of impedance and ECAP signals may be acquired while the patient is in different patient postures or positions, such as sitting, standing, supine, or the like. Additionally, or alternatively, the method may include detecting neural tissue damage based on the impedance and ECAP signals.

(6) Further, the method may include extruding the patient-specific anatomical model along an SC axis to create a three-dimensional model within a structural grid with material index assigned to each element. The geometry and location of the distal SCS leads are mapped into the 3D grids with their material properties assigned. The method may include solving a fully coupled extracellular and intracellular domain (e.g., a Bidomain Model) for electromagnetic fields in the extracellular domain and electrical propagation along neurons in the intracellular domain including dorsal column (DC), dorsal root (DR), or dorsal root ganglion (DRG).

(7) Additionally, the method may include receiving patient responses at one or more pre-selected stimulation configurations and/or patient positions. The patient response may correspond to coverage zones on a body map as indicated on user interface at specific stimulation pulses for each of the pre-selected stimulation configurations.

(8) Furthermore, the method may include using predetermined or user defined stimulation configurations for emitting a stimulation pulse from the at least one electrode, measuring a stimulation return signal in response to the stimulation pulse, and iteratively repeating the emitting and measuring operation of the method for each electrode to form a solution matrix corresponding to the coupled extracellular and intracellular domains.

(9) In an embodiment, a system for modeling patient-specific spinal cord stimulation (SCS). The system may include a lead positioned proximate to a spinal cord (SC). The lead may include at least one electrode configured to acquire impedance and evoked compound action potential (ECAP) signals. The system may also include a system in communication with the lead. The system may include a memory device, a processor and a display. The system may be configured to determine a patient-specific anatomical model based on the impedance and ECAP signals, transform a dorsal column (DC) map template based on a DC boundary of the patient-specific anatomical model, and map the transformed DC map template to the patient-specific anatomical model. The system may also include algorithms to solve extracellular and intracellular domain electrical fields and propagation along neurons. The system may also include the user interfaces to collect patient responses and compare with model solutions.

(10) In an embodiment, a method for differentiating spinal cord (SC) damage. The method may include emitting a stimulation waveform from at least one electrode of a lead. The lead being positioned proximate to a SC. The method may include acquiring impedance and evoked action compound action potential (ECAP) signals. The impedance and ECAP signals are based on the stimulation waveform. The method may further include selecting a first impedance and ECAP measurement and a second impedance and ECAP measurement from the impedance and ECAP signals. The second impedance and ECAP measurement is temporally separated from the first impedance and ECAP measurement. The method may include detecting SC tissue damage based on a difference between the second ECAP measurement and the first ECAP measurement, and between the second impedance measurement and first impedance measurement, and adjusting at

least one therapy parameter to change the stimulation waveform or adjusting the position of the lead based on detection of the SC tissue damage.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) FIG. 1 is a functional block diagram of a spinal cord stimulation programming guidance system, in accordance to an embodiment of the present disclosure.
- (2) FIG. 2 illustrates a neurostimulation system that is a part of or used by one or more of the components of FIG. 1.
- (3) FIG. 3 is a flowchart of a method for determining a patient-specific anatomical model based on impedance and evoked compound action potential.
- (4) FIG. 4 illustrates a lead positioned proximate to a spinal cord, in accordance to an embodiment of the present disclosure.
- (5) FIG. 5 illustrates a lateral view of the lead positioned proximate to the spinal cord of FIG. 4.
- (6) FIG. 6 illustrates a graphical representation of electrical potential measurements at an electrode from the lead in FIG. 4.
- (7) FIG. 7 illustrates a two dimensional cross section of the lead and spinal cord of FIG. 4.
- (8) FIG. 8 is a graphical illustration of impedance measurements from the lead corresponding to a position of the lead relative to the spinal cord tissue of FIG. 7.
- (9) FIG. 9 illustrates a two dimensional cross section of the lead and spinal cord of FIG. 4.
- (10) FIG. 10 is a graphical illustration of impedance measurements from the lead corresponding to a position of the lead relative to the spinal cord tissue of FIG. 9.
- (11) FIG. 11 illustrates a two dimensional cross section of the lead and spinal cord of FIG. 4.
- (12) FIG. 12 is a graphical illustration of impedance measurements from the lead corresponding to a position of the lead relative to the spinal cord tissue of FIG. 11.
- (13) FIG. 13 is a graphical representation of evoked compound action potential signals resulting from a drive signals, according to an embodiment of the present disclosure.
- (14) FIG. 14 is a graphical illustration of a spinal cord model template, according to an embodiment of the present disclosure.
- (15) FIG. 15 is a graphical illustration of an adjusted spinal cord model template based on thickness and characteristic measurements of spinal cord tissue, according to an embodiment of the present disclosure.
- (16) FIG. 16 is a flowchart of a method for transforming a dorsal column map template based on a dorsal column boundary of a patient-specific anatomical model, according to an embodiment of the present disclosure.
- (17) FIG. 17 is an illustration of a dorsal column map template, according to an embodiment of the present disclosure.
- (18) FIG. 18 is an illustration of a meshed dorsal column map template, according to an embodiment of the present disclosure.
- (19) FIG. 19 is an illustration of a translated meshed DC map template, according to an embodiment of the present disclosure.
- (20) FIG. 20 is an illustration of a transformed DC map template, according to an embodiment of the present disclosure.
- (21) FIG. 21 is a flowchart of a method for mapping a patient-specific anatomical model to a transformed DC map template, in accordance to an embodiment of the present disclosure.
- (22) FIG. 22 is an illustration of stimulation return evoked compound action potential signals received by a lead, in accordance to an embodiment of the present disclosure.
- (23) FIG. 23 is an illustration of a graphical user interface of a system, in accordance to an

embodiment of the present disclosure.

(24) FIG. **24** is an illustration of a graphical user interface of a system, in accordance to an embodiment of the present disclosure.

(25) FIG. **25** is an illustration of a graphical user interface of a system, in accordance to an embodiment of the present disclosure.

(26) FIG. **26** is a flowchart of a method for differentiating between spinal cord tissue damage and changes in electrode position based on impedance and evoked compound action potential measurements, in accordance to an embodiment of the present disclosure.

(27) FIG. **27** is a graphical illustration of a stimulation waveform with corresponding impedance and evoked compound action potential measurements magnitudes, in accordance to an embodiment of the present disclosure.

(28) FIG. **28** is a decision table for detecting spinal cord tissue damage, substrate change, and/or movement of a lead, in accordance to an embodiment of the present disclosure.

(29) FIG. **29** is a flowchart for detecting spinal cord tissue damage, substrate change, and/or movement of a lead, in accordance to an embodiment of the present disclosure.

DETAILED DESCRIPTION

(30) While multiple embodiments are described, still other embodiments of the described subject matter will become apparent to those skilled in the art from the following detailed description and drawings, which show and describe illustrative embodiments of disclosed inventive subject matter. As will be realized, the inventive subject matter is capable of modifications in various aspects, all without departing from the spirit and scope of the described subject matter. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.

(31) Embodiments described herein include a patient-specific spinal cord stimulation (SCS) programming guidance system **100** that may be used during SCS implantation, during office visits, and the like. The system **100** may be used by a clinician and/or patient to determine and/or select optimal SCS settings (e.g., amplitude, duration, frequency, type of stimulation pulses, selection of electrode configurations, or the like) that target a region of interest.

(32) FIG. **1** illustrates a functional block diagram of the SCS programming guidance system **100**, that is operated in accordance with the processes described herein and to interface with an NS system **200** (FIG. **2**) as described herein. The system **100** may be a workstation, a portable computer, a tablet computer, a PDA, a cell phone and the like. The system **100** includes an internal bus **101** that may connect/interface with a Central Processing Unit (“CPU”) **102**, ROM **104**, RAM **106**, a hard drive **108**, a speaker **110**, a printer **112**, a CD-ROM drive **114**, a floppy drive **116**, a parallel I/O circuit **118**, a serial I/O circuit **120**, the display **122**, a touchscreen **124**, a standard keyboard **126**, custom keys **128**, and an RF subsystem **130**. The internal bus **101** is an address/data bus that transfers information between the various components described herein. The hard drive **108** may store operational programs as well as data, such as stimulation waveform templates and detection thresholds.

(33) Optionally, the touchscreen **124** may be integrated with the display **122**. The keyboard **126** (e.g., a typewriter keyboard **136**) allows the user to enter data to the displayed fields, as well as interface with the RF subsystem **130**. Furthermore, custom keys **128**, for example, may turn on/off the system **100**. The printer **112** prints copies of reports **140** for a physician to review or to be placed in a patient file, and the speaker **110** provides an audible warning (e.g., sounds and tones **142**) to the user. The parallel I/O circuit **118** interfaces with a parallel port **144**. The serial I/O circuit **120** interfaces with a serial port **146**. The floppy drive **116** accepts diskettes **148**. Optionally, the serial I/O port may be coupled to a USB port or other interface capable of communicating with a USB device such as a memory stick. The CD-ROM drive **114** accepts CD-ROMs **150**.

(34) The CPU **102** typically includes a microprocessor, a micro-controller, or equivalent control circuitry, designed specifically to control interfacing with the system **100** and with the NS system **200**. The CPU **102** may include RAM or ROM memory, logic and timing circuitry, state machine

circuitry, and I/O circuitry to interface with the NS system **200**. The display **122** (e.g., may be connected to the video display **132**). The display **122** displays various information related to the processes described herein. The touchscreen **124** may display graphic information relating to the NS system **200** (e.g., stimulation levels, stimulation waveforms, ECAP measurements) and include a graphical user interface.

(35) The system **100** includes components **52-58** that may employ structures or aspects of various embodiments (e.g., systems and/or methods) discussed herein. In various embodiments, certain components (or operations) may be added, certain components may be combined, certain components may be performed simultaneously, certain components may be performed concurrently, certain components may be split into multiple components, certain components may be performed in a different order, or certain components may be re-performed in an iterative fashion. The components **52-58** may be a part of the CPU **102**. Additionally, or alternatively, the components **52-58** may be algorithms or instructions performed by the CPU **102** stored in memory (e.g., ROM **104**, RAM **106**, hard drive **108**). Optionally, the components **52-58** may be separate modules in communication with the CPU **102**. Optionally, one or more of the components **52-58** may be located external to the system **102**. The system **102** may receive data from the components **52-58** via the RF subsystem **130**.

(36) Generally, the component **52** may be configured to generate lead position geometrical models, which illustrate a position of one or more electrodes on a lead with respect to a spinal cord (SC) tissue of interest based on measured impedance and evoked compound action potential (ECAP) signals. For example, the impedance signal is received by one or more electrodes, which is used to determine a distance between a select electrode and the SC tissue of interest. The geometrical models may additionally define anatomical parameters of interest (e.g., a thickness of cerebral spinal fluid) and landmark locations (e.g., position of the electrodes with respect to the SC tissue of interest) of the SC at select vertebral levels of interest based on the impedance and ECAP signals. For example, based on a structure of the ECAP signal (e.g., slope, peak to peak amplitude, peak latency, peak duration) received by one or more electrodes may be used to determine thickness of the cerebral spinal fluid. The component **52** may also be configured to use lookup tables (e.g., databases) of impedance and ECAP information from computational simulations, which are compared with the measured impedance and ECAP signals to determine a distance from the electrodes to dura/cerebral spinal fluid (CSF) and CSF thickness. Based on the measured impedance and ECAP signals, the component **52** may adjust a SC model template to match the patient's anatomy to generate the lead position geometric models.

(37) The component **54** may be configured to transform (e.g., morph) a dermatomal map template of the SC dorsal column (DC) to fit a derived patient specific DC model based on an anatomy of a patient. Optionally, the transforming of the dermatomal map template by the component **54** may include meshing the dermatomal zone map template and deforming the mesh to adjust to the outer boundary shape of the patient's DC anatomy, such as, using Delaunay triangulation. The outer boundary shape of the patient's DC anatomy may be determined based on the anatomical parameters of interest and landmark locations determined from the lead position geometric model. Additionally, or alternatively, the component **54** may include shifting pixels of the dermatomal zone map template according to a distance the nodes moved from the original mesh to the deformed mesh during the transformation operation. Optionally, variations may be added to the transforming or pixel movement to account for uncertainties in the dermatomal zone size and boundary locations.

(38) Based on the lead position geometric model generated from the component **52** and the derived patient specific DC model from the component **54**, the component **56** may be configured to generate a two-dimensional (2D) and/or three-dimensional (3D) SC model. The SC model may be used to compute electrical fields and neural transmembrane potential in the DC, dorsal root (DR), or dorsal root ganglion (DRG). Further the SC model may be used to determine the activation

regions and activation of mapped dermatomal zones for corresponding electrodes. The SC model may include a fully coupled extracellular and intracellular domain for electromagnetic fields in the extracellular domain and electrical propagation along neurons in the intracellular domain. A technical effect of the system **100** eliminates the use of commercial simulation software using conventional finite element analysis (FEA) and finite difference (FD) methods. An additional technical effect of the system **100** may be to perform a discretization from a 2D SC model to a 3D SC model with the SCS lead that is much faster than other meshing methods used in FEA.

(39) The component **58** may be configured to apply pre-selected or selected electrode stimulation configurations received from the clinician and/or patient. Additionally, or alternatively, the component **58** may be configured to test and refine the SC model based on feedback by the patient. Optionally, the component **58** may include a user-interface, which may include a graphical user interface, for entering stimulation parameters with a display of the corresponding activation regions and activated dermatomal zones.

(40) The RF subsystem **130** includes a central processing unit (CPU) **152** in electrical communication with RF circuitry **154**, which may communicate with both memory **156** and an analog out circuit **158**. The analog out circuit **158** includes communication circuits to communicate with analog outputs **164**. The system **100** may wirelessly communicate with the NS system **200** using a telemetry system. Additionally, or alternatively, the system **100** may wirelessly communicate with the NS system **200** utilize wireless protocols, such as Bluetooth, Bluetooth low energy, Wi-Fi, MICS, and the like. Alternatively, a hard-wired connection may be used to connect the system **100** to the NS system **200**.

(41) Optionally, the system **100** may transmit the stimulation database request to an implantable pulse generator (IPG) **250** (FIG. 2). For example, the user may instruct the system **100** to transmit a stimulation database request from the graphical user interface on the touchscreen **124**, the keyboard **126**, or the like. An NS system **200** receives the request via communication circuitry **255** and transmits the stimulation database stored in memory **261** to the system **100**.

(42) FIG. 2 depicts the NS system **200** that may be a part of or used by one or more of the components **52-58**. The NS system **200** generates electrical pulses for application to tissue of a patient and/or measures/senses electrical signals in response to the electrical pulses according to one embodiment. For example, the NS system **200** may be adapted to stimulate spinal cord tissue, dorsal root, dorsal root ganglion, peripheral nerve tissue, deep brain tissue, cortical tissue, cardiac tissue, digestive tissue, pelvic floor tissue, or any other suitable nerve tissue of interest within a patient's body.

(43) The NS system **200** includes the IPG **250** that is adapted to generate electrical pulses for application to tissue of a patient. The IPG **250** typically comprises a metallic housing or can **259** that encloses a controller **251**, pulse generating circuitry **252**, a charging coil **253**, a battery **254**, a far-field and/or near field communication circuitry **255**, battery charging circuitry **256**, switching circuitry **257**, sensing circuitry **258**, memory **261**, and the like. The controller **251** typically includes a microcontroller or other suitable processor for controlling the various other components of the device. Software code may be stored in memory **261** of the IPG **250** or integrated with the controller **251** for execution by the microcontroller or processor to control the various components of the device.

(44) The IPG **250** may comprise a separate or an attached extension component **270**. If the extension component **270** is a separate component, the extension component **270** may connect with a "header" portion of the IPG **250** as is known in the art. If the extension component **270** is integrated with the IPG **250**, internal electrical connections may be made through respective conductive components. Within the IPG **250**, electrical pulses are generated by the pulse generating circuitry **252** and are provided to the switching circuitry **257**. The switching circuitry **257** connects to outputs of the IPG **250**. Electrical connectors (e.g., "Bal-Seal" connectors) within the connector portion **271** of the extension component **270** or within the IPG header may be employed to conduct

various stimulation pulses. The terminals of one or more leads **210** are inserted within the connector portion **271** or within the IPG header for electrical connection with respective connectors. Thereby, the pulses originating from the IPG **250** are provided to the one or more leads **210**. The pulses are then conducted through the conductors of the lead **210** and applied to tissue of a patient via one or more electrodes (e.g., array of electrodes **211**). Any suitable known or later developed design may be employed for connector portion **272**.

(45) The lead **210** is connected to a flat, thin, paddle structure **214** and connect thereto in a general longitudinal alignment with the length of the paddle structure **214**. The paddle structure **214** may be formed from a medical grade, substantially inert material, for example, polyurethane, silicone, or the like. A front surface or face **212** of the paddle structure **214** is depicted in FIG. 2, which includes an array of electrodes **211** that are spaced apart longitudinally along the length of the paddle structure **214** from a distal end **216** and a proximal end **218**. The array of electrodes **211** are spaced apart across the width of the paddle structure **214**. The spacing of the electrodes **211** can be set accordingly to a target site (e.g., proximate to the SC) and the needed stimulation. The paddle structure **214** itself may have a width such that it spans the entire dorsal column or fits within the epidural space. For example, depending upon the desired implantation site, thoracic or cervical, the paddle structure **214** may be designed to fit into the desired space such that it at least covers the anatomical and physiological midline of the patient. Additionally, or alternatively, the paddle structure **214** may be similar to the paddle structure disclosed in U.S. Provisional Application No. 61/791,288, entitled, "PADDLE LEADS FOR NEUROSTIMULATION AND METHOD OF DELIVERING THE SAME," which is expressly incorporated herein by reference.

(46) Each of the electrodes **211** are mutually separated by non-conducting or insulative material of the paddle, which electrically isolate each electrode **211** from adjacent electrodes **211**. The non-conducting material may include one or more insulative materials and/or biocompatible materials to allow the paddle structure **214** and lead **210** to be implantable within the patient. Non-limiting examples of such materials include polyimide, polyetheretherketone (PEEK), polyethylene terephthalate (PET) film (also known as polyester or Mylar), polytetrafluoroethylene (PTFE) (e.g., Teflon), or parylene coating, polyether bloc amides, polyurethane.

(47) The electrodes **211** may be formed of non-corrosive, highly conductive material. For example, stainless steel, MP35N, platinum, platinum alloys, or the like. The electrodes **211** may be set to function as cathodes, anodes or set to a high-impedance state for a given pulse according to the pulses generated from the IPG **250**. The electrodes **211** may be configured to emit the pulses in an outward radial direction proximate to or within a stimulation target. The electrodes **211** may also be configured to acquire electrical potential measurements (e.g., voltage, current) or electrical signals for the sensory circuit **258**, such as evoked compound activation potentials (ECAP) emitted from the stimulation target. ECAP signals may be generated by neuronal transmembrane currents of neurons activated following or in response to a stimulation pulse from one or more of the electrodes **211**.

(48) Optionally, the IPG **250** may have more than one lead **210** connected via the connector portion **271** of the extension component **270** or within the IPG header. Additionally, or alternatively, the electrodes **211** of each lead **210** may be configured separately to emit current pulses or measure electrical signals emitted from and/or proximate the stimulation target.

(49) It should be noted that in other embodiments the electrodes **211** may be in various other formations or structures. For example, the electrodes **211** may be in the shape of a ring such that each electrode **211** continuously covers the circumference of the exterior surface of the lead **210** to form a percutaneous lead structure. Each of the ring electrodes **211** are separated by non-conducting rings, which electrically isolate each electrode **211** from an adjacent electrode **211**. In another example, the electrodes **211** may be in the shape of a split or non-continuous ring such that the pulse may be directed in an outward radial direction adjacent to the electrodes **211**. Further examples of a fabrication process of the electrodes **211** is disclosed in U.S. patent application Ser.

No. 12/895,096, entitled, “METHOD OF FABRICATING STIMULATION LEAD FOR APPLYING ELECTRICAL STIMULATION TO TISSUE OF A PATIENT,” which is expressly incorporated herein by reference.

(50) The lead **210** may comprise a lead body **272** of insulative material about a plurality of conductors within the material that extend from a proximal end of lead **210** (proximate to the IPG **250**) to its distal end (proximate to the paddle structure **214**). The conductors electrically couple a plurality of the electrodes **211** to a plurality of terminals (not shown) of the lead **210**. The terminals are adapted to receive electrical pulses and the electrodes **211** are adapted to apply the pulses to the stimulation target of the patient. Also, sensing of physiological signals may occur through the electrodes **211**, the conductors, and the terminals. It should be noted that although the paddle structure **214** of the lead **210** is depicted with a five by four array of electrodes **211**, in other embodiments, the lead **210** may be connected to any suitable number of electrodes **211** (e.g., an array with more electrodes **211** than shown in FIG. 2, an array with less electrodes **211** than shown in FIG. 2) as well as terminals, and internal conductors. Additionally, or alternatively, various sensors (e.g., a position detector, a radiopaque fiducial) may be located at or near the distal end **216** of the paddle structure **214** and electrically coupled to terminals through conductors within the lead body **272**.

(51) Although not required for all embodiments, the lead body **272** of the lead **210** may be fabricated to flex and elongate upon implantation or advancing within the tissue (e.g., nervous tissue) of the patient towards the stimulation target and movements of the patient during or after implantation. By fabricating the lead body **272**, according to some embodiments, the lead body **272** or a portion thereof is capable of elastic elongation under relatively low stretching forces. Also, after removal of the stretching force, the lead body **272** may be capable of resuming its original length and profile. For example, the lead body may stretch 10%, 20%, 25%, 35%, or even 50% at forces of about 0.5, 1.0, and/or 2.0 pounds of stretching force. Fabrication techniques and material characteristics for “body compliant” leads are disclosed in greater detail in U.S. Provisional Patent Application No. 60/788,518, entitled “Lead Body Manufacturing,” which is expressly incorporated herein by reference.

(52) For implementation of the components within the IPG **250**, a processor and associated charge control circuitry for an IPG is described in U.S. Pat. No. 7,571,007, entitled “SYSTEMS AND METHODS FOR USE IN PULSE GENERATION,” which is expressly incorporated herein by reference. Circuitry for recharging a rechargeable battery (e.g., battery charging circuitry **256**) of an IPG (e.g., the IPG **250**) using inductive coupling and external charging circuits are described in U.S. Pat. No. 7,212,110, entitled “IMPLANTABLE DEVICE AND SYSTEM FOR WIRELESS COMMUNICATION,” which is expressly incorporated herein by reference.

(53) An example and discussion of “constant current” pulse generating circuitry (e.g., pulse generating circuitry **252**) is provided in U.S. Patent Publication No. 2006/0170486 entitled “PULSE GENERATOR HAVING AN EFFICIENT FRACTIONAL VOLTAGE CONVERTER AND METHOD OF USE,” which is expressly incorporated herein by reference. One or multiple sets of such circuitry may be provided within the IPG **250**. Different pulses on different electrodes **211** may be generated using a single set of the pulse generating circuitry **252** using consecutively generated pulses according to a “multi-stimset program” as is known in the art. Complex pulse parameters may be employed such as those described in U.S. Pat. No. 7,228,179, entitled “Method and apparatus for providing complex tissue stimulation patterns,” and International Patent Publication Number WO 2001/093953 A1, entitled “NEUROMODULATION THERAPY SYSTEM,” which are expressly incorporated herein by reference. Alternatively, multiple sets of such circuitry may be employed to provide pulse patterns (e.g., tonic stimulation waveform, burst stimulation waveform) that include generated and delivered stimulation pulses through various electrodes of one or more leads **211** as is also known in the art. Various sets of parameters may define the pulse characteristics and pulse timing for the pulses applied to the various electrodes **211**.

as is known in the art. Although constant current pulse generating circuitry is contemplated for some embodiments, any other suitable type of pulse generating circuitry may be employed such as constant voltage pulse generating circuitry.

(54) The sensing circuitry **258** may measure an electric potential (e.g., voltage, current) over time of the stimulation target or proximate tissue through at least one of the electrodes **211** that is proximate to the stimulation target. The electric potential (EP) measurements may correspond to the ECAP signal generated by the stimulation target in response to pulses emitted from the electrodes **211**. For example, the sensing circuitry **258** may measure an ECAP signal from an A β sensory fiber or neural tissue of the SC processed from the EP sensed from one or more of the electrodes **211** on the lead **210**. The sensing circuitry **258** may include amplifiers, filters, analog to digital converters, memory storage devices (e.g., RAM, ROM), digital signal processors, and/or the like. Optionally, the sensing circuitry **258** may store the EP in the memory **261**.

(55) The system **100** may be implemented to charge/recharge the battery **254** of the IPG **250** (although a separate recharging device could alternatively be employed), to access the memory **261**, and to program the IPG **250** on the pulse specifications while implanted within the patient. Although, in alternative embodiments separate programmer devices may be employed for charging and/or programming the NS system **200**. The system **100** may be a processor-based system that possesses wireless communication capabilities. Software may be stored within a non-transitory memory of the system **100**, which may be executed by the processor to control the various operations of the system **100**. Optionally, a “wand” **265** may be electrically connected to the system **100** through suitable electrical connectors (not shown). The electrical connectors may be electrically connected to a telemetry component **266** (e.g., inductor coil, RF transceiver) at the distal end of wand **265** through respective wires (not shown) allowing bi-directional communication with the IPG **250**.

(56) The user may initiate communication with the IPG **250** by placing the wand **265** proximate to the NS system **200**. Preferably, the placement of the wand **265** allows the telemetry system of the wand **265** to be aligned with the far-field and/or near field communication circuitry **255** of the IPG **250**. The system **100** preferably provides one or more user interfaces **268** (e.g., graphical user interface, display, touchscreen **124**, keyboard **126**, mouse, buttons, or the like) allowing the user to operate (e.g., adjust the pulse settings) the IPG **250**. The system **100** may be controlled by the user (e.g., doctor, clinician) through the user interface **268** allowing the user to interact with the IPG **250**. The user interface **268** may permit the user to move electrical stimulation along and/or across one or more of the lead(s) **210** using different electrode **211** combinations, for example, as described in U.S. Patent Application Publication No. 2009/0326608, entitled “METHOD OF ELECTRICALLY STIMULATING TISSUE OF A PATIENT BY SHIFTING A LOCUS OF STIMULATION AND SYSTEM EMPLOYING THE SAME,” which is expressly incorporated herein by reference. Optionally, the user interface **268** may permit the user to designate which electrodes **211** are to stimulate (e.g., emit current pulses, in an anode state, in a cathode state) the stimulation target, to measure the ECAP or impedance (e.g., connecting to the sensing circuitry **158**) resulting from the current pulses, remain inactive (e.g., floating), or the like. Additionally, or alternatively, the system **100** may access or download the electrical measurements from the memory **261** acquired by the sensing circuitry **258**.

(57) Also, the system **100** may permit operation of the IPG **250** according to one or more spinal cord stimulation (SCS) programs or therapies to treat the patient. Each SCS program may include one or more sets of stimulation parameters of the pulse including pulse amplitude, stimulation level, pulse width, pulse frequency or inter-pulse period, pulse repetition parameter (e.g., number of times for a given pulse to be repeated for respective stimset during execution of program), biphasic pulses, monophasic pulses, etc., forming a drive signal or stimulation waveform. The IPG **250** may modify its internal parameters in response to the control signals from the system **100** to vary the stimulation characteristics of the stimulation pulses transmitted through the lead **210** to the

tissue of the patient. NS systems, stimsets, and multi-stimset programs are discussed in PCT Publication No. WO 01/93953, entitled “NEUROMODULATION THERAPY SYSTEM,” and U.S. Pat. No. 7,228,179, entitled “METHOD AND APPARATUS FOR PROVIDING COMPLEX TISSUE STIMULATION PATTERNS,” which are expressly incorporated herein by reference.

(58) FIG. 3 is a flowchart of a method **300** for determining a patient-specific anatomical model based on impedance and evoked compound action potential signals. The method **300** may employ one or more of the components **52-58** described above, for example, the component **52**, the controller **251**, the CPU **102**, and/or the CPU **152**. Optionally, the operation of the method **300** may represent actions to be performed by one or more circuits (e.g., the controller **251**) that include or are connected with one or more processors, microprocessors, controller, microcontrollers, Application Specific Integrated Circuits (ASICs), Field-Programmable Gate Arrays (FPGAs), or other logic-based devices that operate using instructions stored in a tangible and non-transitory computer readable medium (e.g., a computer hard-drive, ROM, RAM, EEPROM, flash drive, and/or the like), such as software, and/or that operate based on instructions that are hardwired into the logic of the one or more circuits. For example, the operations of the method **300** may represent actions of or performed by one or more processors when executing programmed instructions stored in a tangible and non-transitory computer readable medium.

(59) In various embodiments, certain steps (or operations) may be omitted or added, certain steps may be combined, certain steps may be performed simultaneously, certain steps may be performed concurrently, certain steps may be split into multiple steps, certain steps may be performed in a different order, or certain steps or series of steps may be re-performed in an iterative fashion. Furthermore, it is noted that the following is just one possible method of determining a patient-specific anatomical model based on impedance and evoked compound action potential. It should be noted, other methods may be used, in accordance with embodiments herein.

(60) One or more methods may (i) acquire impedance and evoked compound action potential (ECAP) signals from a lead positioned proximate to a spinal cord (SC) and (ii) determine a patient-specific anatomical model based on the impedance and ECAP signals.

(61) Beginning at **302**, a lead **402** (shown in FIG. 4) is positioned proximate to a SC **406**. The lead may be similar to the lead **210** with the paddle structure **214** depicted in FIG. 2 or may include other features, such as those described or referenced herein. FIG. 4 is an illustration of a lead placement **400**, and FIG. 5 is an illustration of a lateral view **500** of the lead placement **400**. The lead **402** includes an array of electrodes **511** overlaid on a front surface **512** of a paddle structure **510**, and adjacent to the SC **406**, or specifically, a dura layer **514** of the SC **406** positioned lengthwise along an axis **516**. It should be noted that in other embodiments the electrodes **511** may not be a part of the paddle structure **510**, such as, the percutaneous lead structure as described above. The lead **402** is positioned at a target position, in an epidural space **404** of a patient so as to be in close proximity to a nerve tissue of interest, the SC **406**. For example, the position of the lead **402** enables one or more of the electrodes **511** to detect and/or measure an impedance and/or an ECAP generated by the corresponding neurons of the stimulation target in response to a drive signal emitted by one or more of the electrodes **511**. The stimulation target may include afferent or sensory nerve fibers, such as A β sensory fibers, A δ sensory fibers, C sensory fibers, and/or interneurons.

(62) The lead **402** is connected via a lead body **410** to an IPG **412** (e.g., the IPG **250**). Optionally, the lead **402** may be positioned at a selected vertebral level, which may be used to select an SC model template, as further described herein. FIG. 5 also depicts SC tissue within the dura layer **514**, such as a dorsal column (DC) **506**, white matter **502**, grey matter **504**, and cerebral spinal fluid **508**.

(63) At **304**, a drive signal is emitted from at least one electrode **511** of the lead **402**. For example, the drive signal may be generated from the IPG **412**, such as from generating circuitry (e.g., the generating circuitry **252**), and conducted to at least one of the electrodes **511** via switching circuitry

(e.g., the switching circuitry **257**) and the lead **402**. The drive signal may represent a current pulse (e.g., a monophasic pulse) or a series of current pulses (e.g., a biphasic pulse, tri-phasic pulses), a sinusoidal waveform, a burst waveform, and/or the like which are emitted from at least one of the electrodes **511** with a predetermined amplitude and pulse width. Additionally, or alternatively the drive signal may be a voltage pulse with a predetermined amplitude and pulse width. The drive signal is used by the IPG (e.g., IPG **412**, IPG **250**) and/or the system **100** to determine anatomical parameters of interest (e.g., CSF thickness) and landmark locations (e.g., position of the electrodes **511** with respect to SC tissue of interest) of the SC based on impedance (at **306**) and ECAP signals (at **308**) resulting from the drive signal. Additionally, or alternatively, in connection with FIG. **26**, the drive signal may correspond to a stimulation waveform and be used by the IPG to determine neural tissue damage, changes in the substrate (e.g., composition within the DC **506**), movement of the lead **210**, and/or the like.

(64) Optionally, the drive signal may be a series of pulses. At least one subset of the series of pulses may be shaped (e.g., pulse width, amplitude, frequency) to facilitate measurement of the impedance signal. Additionally, or alternatively, at least another subset of the series of pulses may be shaped to facilitate measurement of the ECAP signal. It should be noted that in at least one embodiment the drive signal may be shaped to facilitate measurement of both the impedance signal and the ECAP signal.

(65) At **306**, an impedance signal is acquired from the lead based on the drive signal. The magnitude of the impedance signal is based on electrical properties, such as the conductivity, of the SC tissue proximate to the electrode(s) emitting the drive signal and/or acquiring the impedance signal. For example, if the proximate SC tissue is primarily epidural fat the impedance signal will have a high magnitude due to the low conductivity of epidural fat. In another example, if the proximate SC tissue is primarily CSF the impedance signal will have a low magnitude due to the high conductivity of the CSF. The impedance signal may be measured and stored in the memory **261**. Based on the impedance signals, the system **100** and/or controller **251** may determine the electrical conductivity of the CSF and/or epidural fat layer of the SC tissue.

(66) The impedance signal may correspond to a discrete impedance value or a calculated impedance over time during the drive signal. For example, the drive signal may be a current pulse emitted from two or more electrodes **511** (e.g., one electrode is in a cathode state, one electrode is in an anode state). Alternatively, the drive signal may be emitted from at least one of the electrodes **511** and the housing (e.g., the can **259**). A voltage may be measured from the two or more electrodes **511** delivering the drive signal by the sensing circuitry **258** and/or the controller **251** comparing the two voltage potentials of the two or more electrodes **511** during the drive signal. Additionally, or alternatively, the voltage may be measured by one or more alternative electrodes **511** (e.g., not emitting the drive pulse) during the drive signal and received by the sensing circuitry **258**. Using the measured voltage and the drive signal, the controller **251** can determine the impedance signal (variable $Z_{sub.c}$), using Equation 1, by dividing the measured voltage (variable $V_{sub.measured}$) by the known stimulation current (variable $I_{sub.stim}$) for the drive signal.

$$Z_{sub.c} = V_{sub.measured} / I_{sub.stim} \quad (\text{Equation 1})$$

(67) In another example, the drive signal may be a voltage pulse emitted from two or more electrodes **511**. Alternatively, the drive signal may be emitted from at least one of the electrodes **511** and the housing (e.g., the can **259**). A measured current may be measured from the at least one electrode **511** emitting the drive signal or by an alternative electrode **511** (e.g., not emitting the drive signal) during the drive signal, and received by the sensing circuitry **258**. Using the measured current and the known stimulation voltage value for the drive signal, the controller **251** can determine the impedance signal (variable $Z_{sub.c}$) using, Equation 2, by dividing the stimulation voltage (variable $V_{sub.stim}$) of the drive signal by the measured current (variable (measured)).

$$Z_{sub.c} = V_{sub.stim} / I_{sub.measured} \quad (\text{Equation 2})$$

(68) It should be noted in various embodiments, one or more of the electrodes **511** may be used for

emitting a stimulation waveform (e.g., the drive signal) and measuring of the impedance signal (or ECAP signal at **308** generated by the corresponding neurons of the stimulation target).

Additionally, or alternatively, a subset of the electrodes **511** may be used for emitting the drive signal and another subset of the electrodes **511** may be used to measure the impedance signal (or ECAP signal at **308**).

(69) Returning to FIG. **3**, at **308**, the method **300** acquires an ECAP signal from the lead **402** resulting from and/or induced by the drive signal. FIG. **6** illustrates a graphical representation **600** of an ECAP signal measured at one or more of the electrodes **511** from the lead **402** during and after the measurement pulse. A horizontal axis **604** represents time, and a vertical axis **602** represents an electrical potential magnitude of the ECAP signal measured at the electrode **511**. The ECAP signal may include a stimulation induced artifact component **608** and an ECAP waveform **606**. The component **608** is an electrical artifact in the sensed ECAP signal due to the measurement pulse delivered by the electrode **511**. The controller **251** and/or sensing circuitry **158** may filter out the component **608** by automatically adjusting the gain concurrently when the drive signal(s) are delivered to the electrodes **511**. An ECAP waveform **606** is measured utilizing the electrode **511** by the sensing circuitry **158**.

(70) At **310**, a distance (e.g., **702-710**) between the at least one electrode and a SC tissue of interest is determined based on the impedance signal. The determination at **310** is further described in connection with FIGS. **7** and **8**. FIG. **7** illustrates a two dimensional (2D) cross-sectional view **700** of the paddle structure **510** of the lead **402** and spinal cord **406** from FIG. **4** at a row **812** (FIG. **8**) of the electrodes **511a-e**. FIG. **8** is a graphical illustration **800** of the impedance signals **806-810** corresponding to drive signals originating or sensed from electrodes **511a-e**, acquired at **304**, at different points in time.

(71) The electrodes **511a-e** are each a distance **702-710**, respectively, away from the dura layer **514** surrounding the CSF **508**. At different points in time (e.g., t_0 , t_1 , t_2 , t_3 , t_4) a corresponding electrode **511a-e** emits the drive signal (e.g., a monophasic current pulse), and a corresponding electrode **511f-j** senses an electrical response (e.g., sensed voltage, sensed current) in response to the drive signal for the impedance signal. It should be noted that in other embodiments, the electrode sensing the electrical response and emitting the drive signal may be interchanged (e.g., electrode **511f** emits the drive signal, electrode **511a** senses the electrical response), located in different columns on the electrode array **511**, or measured from the same electrodes (e.g., electrode **511a-e**) emitting the drive signal. Optionally, more than one electrode may sense the electrical response. Additionally, or alternatively, the same electrode may sense the electrical response for more than one electrode emitting the drive signal. Optionally, more than one electrode may emit the drive signal (e.g., bi-phasic pulse, tri-phasic pulse).

(72) The impedance signal is plotted on the graphical illustration **800**. A vertical axis **802** represents magnitude (e.g., ohms), and the horizontal axis **804** is time. The impedance signal **806** corresponds to a drive signal emitted from the electrode **511a**, the impedance signal **807** corresponds to a drive signal emitted from the electrode **511b**, the impedance signal **808** corresponds to a drive signal emitted from the electrode **511c**, the impedance signal **809** corresponds to a drive signal emitted from the electrode **511d**, the impedance signal **810** corresponds to a drive signal emitted from the electrode **511e**.

(73) The magnitude of the impedance signal **806-810** corresponds to a distance (e.g., **702-710**) from the emitting electrode (e.g., **511a-e**) to the dura layer **514** or CSF **508**. For example, larger distances (e.g., **702**, **710**) yield a larger impedance (e.g., **806**, **810**) because the lead is further from the highly conductive CSF **508**. Alternatively, relatively smaller distances (e.g., **706**) yield a comparatively smaller impedance (e.g., **808**) since the lead is closer to the highly conductive CSF **508**.

(74) The impedance signals **806-810** may be compared by the system **100** and/or the controller **251** to an impedance distance database to determine the distances **702-710**. The impedance distance

database may be stored in memory (e.g., memory **261**, ROM **104**, RAM **106**, a hard drive **108**) and based on traditional three dimensional electromagnetic computation simulations or priori information of experimentally measured impedance measurements and electrode positioned across a patient population. The impedance distance database includes a collection of candidate impedances with associated distances. The impedance distance database may be used as a look up table to match a corresponding impedance signal magnitude with a distance. Additionally, the values of the distances and/or corresponding impedance signals magnitudes of the impedance distance database may be dependent on the structure of the lead **402** and the electrodes **511**. For example, the impedance distance database may have different sets of values of the distances. A first set of distance values correspond to impedance signals for the paddle structure **510**, and a second set of distance values for another structure where the electrodes **511** are in the shape of a ring such that each electrode **511** continuously covers the circumference of the exterior surface of the lead **402**. It should be noted that the impedance distance database may have more than two sets of values of the distances with corresponding impedance signal magnitudes for various other electrode **511** and/or lead **402** structures as described herein.

(75) In at least one embodiment, for each impedance signal **806-810**, the system **100** and/or the controller **251** may find a matching impedance signal magnitude in the impedance distance database (or interpolation with closest data points) with a corresponding distance from an electrode contact to the dura layer **514** or CSF **508**. For example, the system **100** may compare the impedance signal magnitude for the impedance signal **808** to the impedance distance database. The impedance distance database may list the impedance magnitude with a corresponding distance of 0.2 mm. Based on the listed distance, the system **100** may determine that the distance **706** is 0.2 mm from the electrode **511c** to the SC tissue of interest (e.g., the dura layer **514**).

(76) Based on the combination of distances **704-710**, the system **100** may determine an overall position of the paddle based on y and x axes **701** and **703** centered proximate to the paddle **510** on the SC tissue of interest. Optionally, the x and y axes **703**, **701** may be centered on one of the electrodes, for example, the center column electrode, the electrode **511c**, on the paddle structure. The y axis **701** corresponds to a dorsal/ventral position (e.g., dorsal position is based away from the x axis **703**, ventral position is based towards the x axis **703**), for example, based from the distances **702-710**. The x axis **703** corresponds to a medial/lateral position (e.g., medial position is on the y axis **701**, lateral position is based away from the y axis **701** in either a left or right direction along the x axis **703**).

(77) For example, the system **100** and/or the controller **251** may determine the medial/lateral position of the paddle structure **510** based on an interrelation of the magnitude of the impedance signals or morphology (e.g., changes in slope, peaks, rising/falling edges) of a line graph (e.g., an impedance curve **1220**) formed from the impedance signals as further described in connection to FIGS. **9** and **10**. FIG. **9** illustrates a two dimensional (2D) cross section **900** of the paddle structure **510**. The paddle structure **510** is in a laterally shifted position (e.g., left lateral) along the x axis **703** with respect to the SC tissue of interest (e.g., the CSF **508**, the dura layer **514**) relative to the paddle structure **510** shown in FIG. **7**, in the lateral direction of an arrow **901**. Based on the shifted position, a first peripheral column or portion of the electrodes (e.g., the column of the electrodes at **511a**) will be located remotely from the SC tissue of interest, while an opposite second peripheral column or portion of the electrodes (the column at electrode **511e**) is located proximate to the SC tissue of interest.

(78) FIG. **10** is a graphical illustration **1000** of the impedance signals **1006-1010** corresponding to drive signals originating from electrodes **511a-e** of a row **812** of the paddle structure **510** (e.g., acquired at **304**), at different points in time. The impedance signals **1006-1010** may form an impedance curve **1020**. It should be noted that the magnitude of the impedance signals **1006-1007** are approximately the same, and the magnitude of the impedance signals **1008-1010** are also approximately the same. The shifted position of the paddle structure **510** causes a falling edge (e.g.,

change) **1022** between the impedance signals **1007** and **1008**, such that the magnitude of the impedance signal **1008** is lower relative to the magnitude of the impedance signal **1007**. The falling edge **1022** corresponds to the change in distances **924** and **922**, specifically a decrease in distance, respectively, of the electrodes **511b-c** with respect to the SC tissue of interest (e.g., dura layer **514** and/or CSF **508**) in the direction of an arrow **1024**. Conversely, a rising edge, in the direction of the arrow **1024**, may correspond to an increase in distance.

(79) Based on the falling edge **1022** and the interrelation of the magnitudes of the impedance signals **1006-1007** and **1008-1010** being approximately the same, respectively, the system **100** and/or the controller **251** may determine that the falling edge **1022** corresponds to a portion of the paddle structure **510**, such as electrodes **511a-b**, is located remotely from the SC tissue of interest. Since the falling edge **1022** decreases in magnitude in the direction of the arrow **1024**, the system **100** and/or the controller **251** can determine that the paddle structure **510** is shifted laterally.

(80) Additionally, based on the combination of distances of the electrodes **511** from the SC tissue of interest, the system **100** and/or the controller **251** can determine an angle of the paddle structure **510** relative to the SC tissue of interest. For example, the system **100** and/or controller **251** may determine that the paddle structure **510** is positioned at an angle based on a slope of an impedance curve **1220**, as described further in connection to FIGS. **11** and **12**. FIG. **11** illustrates a two dimensional (2D) cross section **1100** of the paddle structure **510**. The paddle structure **510** is in an angled position relative to the axes **701** and **703** with respect to the SC tissue of interest (e.g., the CSF **508**, the dura layer **514**). Based on the angle of the paddle structure **510**, a first peripheral column or portion of the electrodes (e.g., the column of the electrodes at **511a**) is located remotely from the SC tissue of interest, while an opposite second peripheral column or portion of the electrodes (the column at the electrodes **511e**) is located proximate to the SC tissue of interest. Specifically, the first peripheral column is dorsally position to the second peripheral column relative to the SC tissue of interest. Based on the angle, each subsequent distance **1120-1128** of the electrodes **511a-e** from the SC tissue of interest (e.g., dura layer **514** and/or the CSF **508**), in the direction of an arrow **1101**, decreases, respectively, at an approximate rate.

(81) FIG. **12** is a graphical illustration **1200** of the impedance signals **1206-1210** corresponding to drive signals originating from electrodes **511a-e** of the row **812** of the paddle structure **510** (e.g., acquired at **304**), at different points in time. The impedance signals **1206-1210** form an impedance curve **1220**. The decreasing rate of the distances **1120-1128**, based on the angle of the paddle structure **510**, results in an overall decreasing slope in the impedance curve **1220** across the impedance signals **1206-1210** in the direction of an arrow **1224**. The overall decreasing slope may be detected by the system **100** and/or the controller **251**, and used to determine that the paddle structure **510** is positioned at an angle with respect to the SC tissue of interest (e.g., the dura layer **514**, the CSF **508**).

(82) Returning to FIG. **3**, at **312**, a thickness characteristic of the SC tissue of interest is determined based on the ECAP signal. For example, the thickness characteristic may be a CSF thickness **730**, **731** (e.g., a distance from the dura layer **514** to the DC **506**). FIG. **13** illustrates a graphical representation **1300** of ECAP signals **1302-1303** resulting from the drive signal from the electrodes **711c-d**, respectively. A horizontal axis **1312** represents time, and a vertical axis **1310** represents the amplitude of the measured EP. Morphology characteristic (e.g., peak amplitude, width, latency, duration, descending and ascending slopes) of the ECAP signals **1302**, **1303** may be dependent on the thickness characteristic of the SC tissue of interest, such as the CSF thickness **730-731** (FIG. **7**). For example, the ECAP signals **1302** and **1303** each result from two different locations of electrodes **711c-d** emitting drive signals with respect to the CSF thickness **730** and **731**, respectively. The signals **1302** and **1303** also include, at time **1314**, a minimum peak **1316** and **1318** at time **1314** and a maximum peak **1317** and **1319** from the ECAP signals with different peak to peak magnitudes **1320** and **1322**, respectively. Generally, greater CSF thickness will be correlated to lower ECAP peak to peak magnitudes, since the lead is further from the neural fiber

population.

(83) The system **100** and/or the controller **251** may compare one or more ECAP signals features representing the morphology of the ECAP signal **802** such as a slope, a maximum and/or minimum amplitude, time delay from onset of stimulation to peak ECAP amplitude, or the like, with an ECAP database to determine the thickness characteristic of the SC tissue of interest at or near the corresponding electrode (e.g., the electrode **711c-d**). Based on the combination of thickness measurements for each electrode, the system **100** and/or the controller **251** can determine an overall thickness of the SC tissue of interest. The ECAP database may be stored in memory (e.g., memory **261**, ROM **104**, RAM **106**, a hard drive **108**) and based on traditional three dimensional electromagnetic computation simulations or priori information of experimentally measured ECAP signals and electrode positioned across a patient population. The ECAP database includes a collection of candidate ECAP signal features with associated thickness characteristics of the SC tissue of interest. The ECAP database may be used as a look up table to match one or more ECAP signal features with thickness characteristic of SC tissue of interest.

(84) In at least one embodiment, a peak to peak **1320** measurement from the ECAP signal **1302** may be measured by the system **100** and/or the controller **251**, and compared with the ECAP database to find a matching peak to peak ECAP signal in the ECAP database (or interpolation with closest data points) with a corresponding CSF thickness. For example, the system **100** may compare the peak to peak **1320** to the ECAP database. The ECAP database may list a peak to peak matching the peak to peak **1320** with a corresponding CSF thickness of 2.8 mm. Based on the listed CSF thickness, the system **100** may determine that the CSF thickness **730** is 2.8 mm.

(85) At **314**, the method **300** adjusts an SC model template **1400** based on the distance and thickness characteristic. FIG. **14** is a graphical illustration of a SC model template **1400**. The SC model template **1400** may be selected from a SC model template database stored in memory (e.g., ROM **104**, RAM **106**, a hard drive **108**) by the clinician using the system **100**. Each of the SC model templates within the SC model template database may correspond to a vertebral level of the SC. For example, the clinician may select the vertebral level corresponding to a location of the lead **402**, paddle structure **510**, and/or one or more electrodes **511** using the system **100**. Based on the vertebral level, the SC model template **1400** may be selected. Optionally, the SC model template may include a coordinate origin **1403** centered (e.g., along the x and y axes **1402**, and **1404**) relative to SC tissue **1401**.

(86) After the selection of the SC model template **1400**, the system **100** and/or the controller **251** may adjust the SC model template **1400** based on the distance and thickness characteristic operations determined at **310** and **312**. FIG. **15** is a graphical illustration of an adjusted SC model template **1500**. Based on the distance and thickness characteristic measurements, the system **100** and/or the controller **251** may determine ratios along the x and y axes **1402**, **1404** to scale the SC model template **1400** resulting in the adjusted SC model template **1500**, which represent the SC of the patient.

(87) For example, the SC model template **1400** has a CSF thicknesses **1406** based on a position of a lead **1412**. The thickness characteristic measurements determined at **312** correspond to CSF thicknesses **1506**. The system **100** may determine a ratio along the x and y axes **1402**, **1404** based on the CSF thicknesses **1506** compared with the CSF thicknesses **1406**. The ratio is used to adjust the SC model template **1400** to form the adjusted SC model template **1500**. The system **100** may further adjust the position (e.g., medial/lateral, distance from the dura layer, angle relative to the SC tissue) of the lead **1412** in the SC model template **1400**. The position of the lead **1412** is adjusted based on the distance characteristics determined at **310** with respect to the adjusted SC model template **1500** to determine the adjusted position of the lead **1412**.

(88) Optionally, the SC model template **1400** may also be adjusted based on one or more medical images acquired by a medical imaging system (e.g., magnetic resonance imaging, computed tomography, X-ray, or the like). The one or more medical images of the patient may be imported by

the method **300** for determination of patient anatomy and electrode position. For example, segmentation of pre-operative MRI could provide detailed information about SC tissue geometric structure. In another example, once the lead **402** is implanted within the patient, post-operative CT or X-ray may be used to acquire positions of the electrodes **511**. In another example, for an MRI compatible SCS system, both SC anatomy and location of the electrodes **511** may be obtained from post-operative MRI.

(89) The medical images may also be used for image-based calibration of the impedance distance and/or ECAP databases. For example, the system **100** and/or controller **251** may use the impedance signal for investigating SC tissue properties, such as the electrical conductivity of the CSF layer or of the epidural fat, to be used in building and/or updating the impedance distance database. In another example, the impedance distance database and/or ECAP database may be based on nominal values of tissue conductivity based on priori information. Based on the medical images, the impedance distance and ECAP signals corroborated with positioned information of the electrodes **511** and/or SC tissue properties are used for minor adjustment of conductivity away from these nominal values.

(90) Additionally, or alternatively, additional impedance and ECAP signals may be acquired. Each set of impedance and ECAP signals may correspond to different patient postures or positions, such as sitting, standing, supine, or the like. For example, a first set of impedance signal(s) and ECAP signal(s) may be acquired by the sensing circuitry **258** while the patient is in a first position, such as in a sitting position. When the patient adjusts to a second position, such as a standing position, the second set of impedance and ECAP signals may be acquired and so on for all desired postures. It should be noted that in other embodiments more than two different patient positions may be used. Optionally, the impedance and ECAP signals corresponding to multiple positions of the patient may be stored in a position measurement database on memory (e.g., memory **261**, ROM **104**, RAM **106**, hard drive **108**). Corresponding models (e.g., patient-specific anatomical models) at different postures may be built with associated changes in electrode location and SC anatomy. Through stimulation configurations with each patient-specific anatomical model, SCS programming guidance with each posture may be established and stored in the NS system **200** and/or the SCS programming guidance system **100**.

(91) A technical effect of acquiring impedance and ECAP signals at multiple positions allow the patient-specific anatomical model to be configured for different postures for SCS programming and stored in memory (e.g., ROM **104**, RAM **106**, hard drive **108**). Allowing, patients to implement the desired SCS programming when using a graphical user interface of the system **100** when the posture or position of the patient changes.

(92) FIG. **16** is a flowchart of a method **1600** for transforming (e.g., morphing) a DC map template based on a DC boundary of the patient-specific anatomical model. The method **1600** may be employed by one or more of the components **52-58** described above, for example, the component **54**. The method **1600** may employ structures or aspects of various embodiments (e.g., systems and/or methods) discussed herein. In various embodiments, certain steps (or operations) may be omitted or added, certain steps may be combined, certain steps may be performed simultaneously, certain steps may be performed concurrently, certain steps may be split into multiple steps, certain steps may be performed in a different order, or certain steps or series of steps may be re-performed in an iterative fashion. Furthermore, it is noted that the following is just one possible method of transforming a DC map template based on a DC boundary of the patient-specific anatomical model. It should be noted, other methods may be used, in accordance with embodiments herein.

(93) A technical effect of the method **1600** is a transformed DC map template (e.g., a transformed DC map template **2000** of FIG. **20**) that may be used to automatically identify which dermatomal zones are activated during SCS. Additionally, the transformed DC map template may be used to automatically calculate the area of activation or number of fibers activated in each zone. It should be noted although the method **1600** is described transforming a 2D DC map template, in at least

one embodiment, a 3D DC map template may be transformed using the method **1600**.

(94) One or more methods may (i) generate a meshed DC map template and (ii) translate the mesh nodes of the meshed DC map template based on a patient-specific anatomical model.

(95) Beginning at **1602**, the method **1600** automatically traces outer DC boundaries **1502** and **1704** of a DC map template (e.g., dermatomal zone map template is shown in FIG. **17**) **1700** and a patient-specific anatomical model (e.g., the adjusted SC model template **1500**). FIG. **17** is an illustration of the DC map template **1700**. The DC map template **1700** includes dermatomal zones **1702** separated or bounded by internal zone boundaries **1706** and/or the DC boundary **1704**. The system **100** may trace the outer DC boundaries **1502** and **1704** of the DC map template **1700** and the adjusted SC model template **1500**.

(96) At **1604**, the method **1600** transforms the boundaries of the DC map template and the patient-specific anatomical model. The system **100** may translate and/or scale the DC boundaries **1502** and **1704** of the adjusted SC model template **1500** and the DC map template **1700** so each DC boundary **1502** and **1704** are overlapping. For example, the minimum and maximum value of the DC boundaries **1502** and **1704** along an x and y axes.

(97) At **1606**, the method **1600** generates a meshed DC map template **1800**. FIG. **18** illustrates the meshed DC map template **1800**. The meshed DC map template **1800** includes the DC map template **1700** overlaid with a mesh **1804**. The mesh **1804** is subdivided into multiple mesh nodes **1802** formed as a triangle. It should be noted that in other embodiments the mesh nodes **1802** may be formed as other shapes, for example, rectangles, parallelograms, or the like. The size of the mesh nodes **1802** may be based on a user-specified selection by the clinician using the system **100**. It should be noted that in other embodiments the size and number of mesh nodes **1802** may be greater than or less than what is shown in FIG. **18**. Optionally, the size and number of mesh nodes **1802** may be based on the computational limitations of the system **100**. For example, if the system **100** has limited computational power, the size of the mesh nodes **1802** may increase (and the number of mesh nodes **1802** will decrease) to allow a predetermined amount of computational time needed at **1608**.

(98) At **1608**, the method **1600** translates mesh nodes of the meshed DC map template based on the patient-specific anatomical model. The locations of the mesh nodes **1802** are shifted, as shown in FIG. **19**, such that the mesh nodes **1802** lying on the DC boundary (e.g., the mesh nodes **1802a**) of the DC map template **1700** are translated to the boundary of the patient-specific anatomical model (e.g., the adjusted SC model template **1500**).

(99) FIG. **19** illustrates a translated meshed DC map template **1900**. The translated meshed DC map template **1900** may be formed using a triangulation technique algorithm (e.g., DeLaunay algorithm). For example, the system **100** may construct a background triangulation between an edge of the DC boundary **1704** of the DC map template **1700** and a set of sample points located on the DC map template **1700**. The sample points may be received by the system **100** from the clinician or automatically selected based on contours of the DC map template **1700**. The system **100** may further define descriptors of each mesh node **1802** with respect to the background triangulation, such as using barycentric coordinates within each triangle formed during the background triangulation.

(100) Once the descriptors are defined, the system **100** may adjust the background triangulation to incorporate the desired modification of the DC boundary **1704** to that of the DC boundary **1502** of the adjusted SC model template **1500** to form a transformed DC map template **2000** as shown in FIG. **20**. Optionally, the system **100** may convert the descriptors of each mesh node **1802** to Cartesian coordinates based on the adjusted background triangulation. A technical effect of the translation operation is a transforming of the external DC boundary **1704** and the internal zone boundaries **1706** of the DC map template **1700**.

(101) Optionally, variations may be added during the translation operation at **1608** to account for uncertainties in dermatomal zone sizes and boundary locations. For example, artificial noise may

be added during the movement such that a total distance moved by each mesh node **1802** may be adjusted by a small value using a random number generator centered on zero within the system **100**. Additionally, or alternatively, variations may be added by adjusting the spacing of the mesh nodes **1802** or spacing of the sample points.

(102) At **1610**, the method **1600** calculates a shifted distance of the mesh nodes **1802**. For example, the system **100** may calculate distance based on a position of one or more mesh nodes **1802** from before the translation operation at **1608** to a position of the one or more mesh nodes **1802** after the translation operation at **1608**. Optionally, the method **1600** may include applying an image filter, such as an averaging image filter, based on a user-specified pixel size. The user specified pixel size may be received by the system **100** through the user interface. Additionally, or alternatively, the user specified pixel size may be predetermined and stored in memory (e.g., ROM **104**, RAM **106**, hard drive **108**). The averaging image filter may be used to blend pixel locations of the transformed DC map template **2000**.

(103) FIG. **21** is a flowchart of a method **2100** for mapping the patient-specific anatomical model to the transformed DC map template. The method **2100** may be employed by one or more of the components **52-58** described above, for example, the component **56**. The method **2100** may employ structures or aspects of various embodiments (e.g., systems and/or methods) discussed herein. For example, a patient-specific anatomical model may be generated using the method **300** described above. In various embodiments, certain steps (or operations) may be omitted or added, certain steps may be combined, certain steps may be performed simultaneously, certain steps may be performed concurrently, certain steps may be split into multiple steps, certain steps may be performed in a different order, or certain steps or series of steps may be re-performed in an iterative fashion. Furthermore, it is noted that the following is just one possible method mapping the patient-specific anatomical model to the transformed DC map template. It should be noted, other methods may be used, in accordance with embodiments herein.

(104) Beginning at **2101**, the method **2100** maps the transformed DC map template **2000** to the patient-specific anatomical model. For example, the transformed DC map template **2000** and the adjusted SC model template **1500** may be one or more 2D geometries based on an X-Y plane (e.g., defined by the axes **703** and **701**) based on a row of electrodes (e.g., **812**) of the electrode array **511**. The system **100** may define a coordinate origin (e.g., the coordinate origin **1403**) aligned for both the transformed DC map template **2000** and the adjusted SC model template **1500** located at the distal end (e.g., the distal end **216**) of the lead **402** at the Z axis (e.g., the axis **516**), centered on the adjusted SC model template **1500** (e.g., for the x and y direction). Optionally, a file may be generated by the system **100** containing all of the dimensions of the electrodes **511** (e.g., size of the electrodes, spacing between electrodes, electrode layout design, and the like).

(105) At **2102**, the method **2100** extrudes the patient-specific anatomical model along the Z axis defined by the SC to create a three dimensional (3D) grid. The system **100** may extrude along the Z axis (e.g., the axis **516**) defined by the SC along the lead **402** (or paddle structure **510**) to create the 3D patient-specific anatomical structure. Optionally, the 3D patient-specific anatomical structure may be bounded by a 3D rectangular box to enclose the electrode array(s) **511** and SC tissue. The anatomical contours of the adjusted SC model template **1500** in the X-Y plane may be mapped into a 2D grid in the X-Y plane with pre-determined dx and dy increments. A material index (e.g. based on electrical conductivity) for the various SC tissues may be assigned by the system **100** for each grid point. The 2D grids with material index are duplicated along the Z axis to create a 3D grid within the rectangular box of the model. Optionally, the electrodes **511** and paddle structure **510** or lead **402** is mapped into the 3D grids with a corresponding material index.

(106) At **2104**, the method **2100** emitting a stimulation pulse from the at least one electrode (e.g., the electrode **511a**). The stimulation pulse may be a simulated unit pulse (e.g., constant current or voltage) from at least one electrode within the 3D patient-specific anatomical model.

(107) At **2106**, the method **2100** measures an electric field generated in response to the stimulation

pulse based on the 3D patient-specific anatomical model. For example, the electric field generated may be a simulated response based from a bidomain model (e.g., extracellular and intracellular domain) as corresponding to a position of the at least one electrode within the 3D patient-specific anatomical model.

(108) At **2108**, the method iteratively repeats the emitting and measuring operations at **2104** and **2106** for each electrode of the 3D patient-specific anatomical model to form a solution matrix corresponding to a bidomain model. The solution matrix may be formed by the system such that the matrix deposition/factoring would allow post processing for any combinations of stimulation contact configurations based on the superposition principle. For example, based on the superposition principle of the measured stimulation return signals for each individual electrodes **511** (e.g., **511a**, **511b**, **511c**, **511d**, **511e**) within a selected combination is the sum of the stimulation return signals. A technical effect of the solution matrix is that the need to solve for each contact configuration tested is not needed, and therefore, greatly speeds up the calculation for the activated dermatomal zones.

(109) Optionally, the method **2100** may include adjusting the patient-specific anatomical model based on the stimulation return signals (e.g., actual dermatomal zone activations) in response to emitted stimulation signals from at least one of the electrodes **2208**. The stimulation return signal may include sensed ECAP signals **2206** made across a subset of electrodes **2208** (e.g., the electrodes **511** within the box) of the lead **402**, and may be used to determine the activated dermatomal zones within the DC. FIG. 22 illustrates an example, when an SCS signal is emitted from the electrode **511f** in a center column **2204**, activation of fibers within the DC is expected near the DC midline **2202**, and ECAP signals would propagate longitudinally (e.g., along a Z axis **2209**) along the SC tissue. The propagation is reflected from the sensed ECAP **2206** of the central column **2207** corresponding to electrodes **511** above the emitting electrodes **511f** along the Z axis **2209**. By adjusting the amplitude of the SCS signal emitted from the electrode **511f**, the first sensed ECAP signal (e.g., the stimulation return signal) at the lowest amplitude could be used as the estimated stimulation threshold. The sensed ECAP signals **2206** of the subset of electrodes **2208** may be used to refine the model location, such as adjusting the solution matrix, of activated dermatomal fiber tract zones for given stimulation configurations.

(110) Additionally, or alternatively, a cross impedance may be determined by the system **100** and/or controller **251** based on the sensed ECAP signals **2206**. For example, the cross impedance (variable $Z_{\text{sub.c}}$) may be equal to the ECAP signal (variable $V_{\text{sub.sense}}$) divided by stimulation current of the SCS signal (variable $I_{\text{sub.stim}}$) as noted in Equation 3. This cross impedance may be used concurrently with the impedance signal measured at **306**. Optionally the cross impedance may be used instead of the impedance signal measured at **306**, for example, if the electrodes **511** have a high polarized impedance.

$$Z_{\text{sub.c}} = V_{\text{sub.sense}} / I_{\text{sub.stim}} \quad (\text{Equation 3})$$

(111) The technical effect of the solution matrix used concurrently with the 3D patient-specific anatomical model forms the bidomain model. The bidomain model may be a finite element analysis (FEA) solution coupled with the biophysical cellular model of neural elements to determine the effect of SCS on the transmembrane potentials of nerve fibers in the SC. This allows the clinician to detect and locate sites of neural activation resulting from the SCS emitted from one or more of the electrodes **511**. The biophysical cellular model may be a predetermined template included within the 3D patient-specific anatomical model used to define electrical and geometrical properties of a neuron for an applied stimulation from at least one of the electrodes **511**. For example, the biophysical model may determine the response of a neuron based on an electrical characteristic of the applied stimulation pulse (e.g., amplitude, frequency, pulse width). The biophysical cellular model may include transmembrane ion channels, transmembrane capacitance, intracellular conductance, applied stimulation fields or the like.

(112) In at least one embodiment, the graphical user interface of the system **100** may include

graphical icons, scrollbars, buttons, and the like which may receive or detect user or touch inputs **134** for the system **100** when selections are made by the user. For example, the graphical user interface may allow the user to test the neural response to various pre-selected electrode configurations for input validation. FIG. **23** is an illustration of one possible graphical user interface (GUI) **2400** of the system **100**. The GUI **2400** illustrates a pre-selected electrode configuration **2402** of the NS **200**. The pre-selected electrode configuration **2402** may illustrate which electrodes are emitting SCS (e.g., in a cathode state, in an anode state). Additionally, or alternatively, the GUI **2400** may allow the clinician to test the pre-selected electrode configuration **2402** at several different patient postures, such as sitting, standing, supine, or the like. For example, patient stimulation responses at different patient postures provides input into a body dermatomal map **2404** on the display **122** corresponding to actual dermatomal zone activation in response to stimulations at the pre-selected electrode configuration **2402**. A simulated DC activation region **2406** (e.g., based on the transformed DC map template **2000**) is also displayed on the GUI **2400** based on the solution matrix of the 3D patient-specific anatomical model. The simulated DC activation region **2406** displays simulated dermatomal zones that are activated corresponding to the different patient postures at the pre-selected electrode configuration **2402**. The actual and simulated activated dermatomal zones may automatically be compared by the CPU **102** with mapped zones **2408** of the DC based from patient responses at the different patient postures. By using activation regions from the simulation and dermatomal zones from the patient response, an automated algorithm stored in memory (e.g., ROM **104**, RAM **106**, hard drive **108**) and executed by the CPU **102** to refine or adjust the 3D patient-specific anatomical model parameters, including dermatomal zone locations **2410** of the DC.

(113) Optionally, the GUI **2400** may include use of a predetermined or user-defined trolling algorithm that steps through a selected set of electrode configurations. In at least one embodiment a GUI **2500**, as shown in FIG. **24**, may allow the clinician to define model parameters such as stimulation amplitude **2502**, pulse width **2504**, and/or to select electrode configuration(s) **2506** from an existing library (e.g., stored in the ROM **104**, RAM **106**, or hard drive **108**) or to define a custom set of configurations. The selected configurations **2506** may be simulated from the mapped patient-specific model (e.g., from the method **2100**) and the results may be displayed as an illustration of activated dermatomal zone locations **2508** on the display **122**.

(114) Additionally, or alternatively, a GUI **2600** of the system **100**, as shown in FIG. **25**, may display an illustration with the solved activation areas **2604** and mapped dermatomal zones **2603** corresponding to an electrode configuration **2602**. The GUI **2600** may be used to test different SCS settings that best target specific painful dermatomes, or to automatically determine the optimal settings using an automated optimization routine. Further, the mapped dermatomal zones **2603** display the amount (e.g., area in each zone, number of fibers in each zone) of dermatomal zones activated for each electrode configuration **2602** illustrated as activation area **2604**.

(115) Additionally, or alternatively, in connection with a method **2650** shown in FIG. **26**, the impedance signal acquired at **306** (shown in FIG. **3**) and the ECAP signal acquired at **308** may be used by the controller **251** to differentiate between a change in position or movement of the lead **402** (shown in FIG. **4**) and neural tissue damage of the SC or substrate changes proximate to the lead **402**.

(116) Neural tissue damage may occur during implantation of the lead **402** into the patient, or stimulation of the neurons of the stimulation target in response to the drive signal, and/or the like. For example, pressure applied to the SC by the lead **402** during implantation damages the corresponding neural tissue. Alternatively, stimulation may cause neuronal tissue damage through over-activation of neurons or generation of potentially harmful electrochemical reactions. Damaged neurons may not generate an ECAP in response to the drive signal, and thereby not contributing to the ECAP signal reducing the magnitude of the ECAP signal (e.g., the peak to peak magnitude **1320** of FIG. **13**) relative to non-damaged neurons in response to the drive signal.

(117) Substrate changes correspond to changes in a composition of tissue surrounding the CSF (e.g., the CSF **508** of FIG. 5) and lead **402**. For example, the immune system of the patient may respond and/or react to the presence of the lead **402** within the epidural space **404** or a disease progression within the SC tissue by generating connective tissue around the lead **402** and/or the electrodes **511**. The connective tissue may encapsulate and/or surround portions of the lead **402**, displacing or compressing the CSF **508**. The connective tissue may reduce the conductivity of the tissue between the electrodes **511** and the stimulation target affecting the impedance signal measured by the IPG **412**.

(118) FIG. 26 illustrates a flowchart of the method **2650** to differentiate between neural damage of the SC, substrate change, and lead or electrode position changes based on the impedance and ECAP measurements. The method **2650** may employ structures or aspects of various embodiments (e.g., systems and/or methods) discussed herein. Optionally, the operations of the method **2650** may represent actions to be performed by one or more circuits (e.g., the controller **251**) that include or are connected with processors, microprocessors, controllers, microcontrollers, Application Specific Integrated Circuits (ASICs), Field-Programmable Gate Arrays (FPGAs), or other logic-based devices that operate using instructions stored in a tangible and non-transitory computer readable medium (e.g., a computer hard drive, ROM, RAM, EEPROM, flash drive, or the like), such as software, and/or that operate based on instructions that are hardwired into the logic of the. For example, the operations of the method **2650** may represent actions of or performed by one or more processors when executing programmed instructions stored in a tangible and non-transitory computer readable medium.

(119) In various embodiments, certain steps (or operations) may be omitted or added, certain steps may be combined, certain steps may be performed simultaneously, certain steps may be performed concurrently, certain steps may be split into multiple steps, certain steps may be performed in a different order, or certain steps or series of steps may be re-performed in an iterative fashion. It should be noted, other methods may be used, in accordance with embodiments herein.

(120) One or more methods may (i) emit a stimulation waveform from at least one electrode of a lead, (ii) acquire impedance and evoked compound action potential (ECAP) signals, (iii) select a first impedance and ECAP measurement and a second impedance and ECAP measurements from the impedance and ECAP signals, (iv) detect spinal cord (SC) tissue damage based on a difference between the second ECAP measurement and the first ECAP measurement, and (v) adjust at least one stimulation parameter to change the stimulation waveform or adjust the location of the lead **402** based on detection of the SC tissue damage.

(121) Beginning at **2652**, the lead **402** (shown in FIG. 4) emits a stimulation waveform from at least one electrode **511** (shown in FIG. 5). The stimulation waveform may be similar to and/or the same as the drive signal at **304**. For example, the stimulation waveform may be generated from the IPG **412**, such as from generating circuitry (e.g., the generating circuitry **252** of FIG. 2), and conducted to at least one of the electrodes **511** via switching circuitry (e.g., the switching circuitry **257**) and the lead **402**. The stimulation waveform may represent a current pulse (e.g., a monophasic pulse) or a series of current pulses (e.g., a biphasic pulse, tri-phasic pulses), a sinusoidal waveform, a burst waveform, and/or the like which are emitted from at least one of the electrodes **511** with a predetermined amplitude and pulse width. Additionally, or alternatively the stimulation waveform may be a voltage pulse with a predetermined amplitude and pulse width. Optionally, the stimulation waveform may be repeatedly emitted by the electrodes **511** based on an SCS program.

(122) At **2654**, the lead acquires impedance and ECAP signals. The impedance and ECAP signals are generated in response to the stimulation waveform. As further described in connection to **306** of FIG. 3, the impedance signal may be a discrete impedance value measured periodically by the controller **251** or a calculated impedance measured continuously over time during the stimulation waveform.

(123) FIG. 27 is a graphical illustration of a stimulation waveform **2702** with a corresponding

impedance signal **2748** and ECAP measurements **2760**. The stimulation waveform **2702**, the impedance signal **2748**, and the ECAP measurements **2760** are plotted along a horizontal axis **2714** representing time.

(124) The stimulation waveform **2702** may be emitted from one or more electrodes **511** as shown in FIG. 5. The stimulation waveform **2702** may be formed by a series of pulses **2704-2712** emitted over time represented along the horizontal axis **2714** with an EP magnitude (e.g., current, voltage) represented by the vertical axis **2716**. Parameters for the pulses **2704-2712** such as pulse width, amplitude, frequency, and/or the like may be based on the SCS program.

(125) The impedance signal **2748** is formed by impedance measurements **2750-2758** plotted with respect to a vertical axis **2718** representing a magnitude (e.g., ohms) acquired during the pulses **2704-2712** of the stimulation waveform **2702**. Additionally, or alternatively, in other embodiments the impedance signal **2748** may be measured continuously by the sensing circuitry **258** and/or controller **251**.

(126) The impedance signal **2748** may be acquired similar to and/or the same as the impedance signal acquired at **306** of FIG. 3. For example, the pulses **2704-2712** forming the stimulation waveform **2702** may be emitted by the electrodes **511d** (e.g., in an anode state) and **511h** (e.g., in a cathode state). An electric potential or voltage may be measured across the electrodes **511d** and **511h** by the sensing circuitry **258** and/or the controller **251**. For example, the sensing circuitry **258** may compare the voltage potentials at the electrodes **511d** and **511h** during each of the pulses **2704-2712**. Using Equation 1, the controller **251** may determine impedance measurements **2750-2758** forming the impedance signal **2748** by dividing the measured voltage during each pulse **2704-2712** by the corresponding amplitude of the pulses **2704-2712**.

(127) The ECAP measurements **2760** may correspond to a plurality of peak to peak measurements **2762-2770** plotted with respect to a vertical axis **2720** representing magnitude. The ECAP measurements **2760** may be derived from ECAP signals measured at one or more of the electrodes **511** during the stimulation waveform **2702** and received by the sensing circuitry **258**.

(128) For example, the electrode **511h** may measure the EP during each of the pulses **2704-2712**. The EP may be generated from neurons of the stimulation target in response to the pulses **2704-2712** emitted by one or more electrodes **511**. The measured EP measurements form an ECAP signal for each pulse **2704-2712**, such as the ECAP signal **1302** and/or **1303** shown in FIG. 13. The system **100** and/or the controller **251** may determine when the maximum peak (e.g., **1317**, **1319**) and minimum peak (e.g., **1316**, **1318**) occurs based on changes in the slope of the ECAP signal. For example, the controller **251** may determine when the maximum peak **1317** occurs based on when the slope changes magnitude from positive to negative. In another example, the controller **251** may determine when the minimum peak **1316** occurs when the slope changes from negative to positive.

(129) The controller **251** may determine the peak to peak measurements **2762-2770** based on a difference in magnitude (e.g., EP) between the maximum peak (e.g., **1317**, **1319**) and the minimum peak (e.g., **1316**, **1318**) for each ECAP signal corresponding to the pulses **2704-2714**.

(130) Returning to FIG. 26, the controller **251** at **2658** selects a first impedance and ECAP measurement and a second impedance and ECAP measurement from the impedance and ECAP signals. The second impedance and ECAP measurement may be temporally separated from the first impedance and ECAP measurement.

(131) For example, the selected impedance and ECAP measurements may correspond to two different pulses within the stimulation waveform **2702**. The controller **251** may select the impedance measurement **2752** and the peak to peak ECAP measurement **2764** corresponding to the pulse **2706** as the first impedance and ECAP measurement, and the impedance measurement **2754** and the peak to peak measurement **2766** as the second impedance and ECAP measurement. It should be noted in other embodiments the ECAP measurements may correspond to amplitudes of the maximum peak (e.g., **1317**, **1319**), amplitudes of the minimum peak (e.g., **1316**, **1318**), and/or the like of the ECAP signal.

(132) At **2660**, the controller **251** may detect damage to neural tissue of SC, a substrate change, or movement of the lead **402** (FIG. **4**). In connection with FIGS. **28** and **29**, the controller **251** may detect and/or determine when damage to the SC tissue, the substrate change, and/or movement of the lead **402** based on a difference between the second impedance and/or ECAP measurement and the first impedance and/or ECAP measurement.

(133) FIG. **28** illustrates a decision table **2800** utilized by the controller **251** for detecting SC tissue damage, substrate change, and/or movement of a lead. The decision table **2800** includes an impedance column **2802** and an ECAP amplitude column **2804** with a corresponding determination listed in the column **2806**. The controller **251** may determine SC tissue (e.g., neural tissue) damage, substrate change, and/or movement of the lead **402** based on a relationship between the first impedance and ECAP measurement and the second impedance and ECAP measurement. For example, the controller **251** may detect SC tissue damage based on a predetermined combination of i) an ECAP difference between first and second ECAP measurements and ii) an impedance difference between first and second impedance measurements.

(134) The impedance column **2802** corresponds to differences determined by the controller **251** between the first impedance measurement (e.g., the impedance measurement **2752**) and the second impedance measurement (e.g., the impedance measurement **2754**) selected at **2658** of FIG. **26**.

(135) For example, the controller **251** may determine whether the impedance increases, decreases, and/or does not change from the first impedance measurement to the second impedance measurement based on a predetermined impedance threshold. The predetermined impedance threshold may be stored in the memory **261**, and correspond to a minimum amount of change between the two selected impedance measurements that will be determined and/or verified by the controller **251** as an increase and/or decrease in impedance.

(136) For example, the predetermined impedance threshold may correspond to an amount of change between the impedance measurements that is greater than electrical noise (e.g., additive noise, electromagnetic interference, signal-to-noise ratio) generated by the operation of the IPG **250**. The predetermined impedance threshold may be a percentage corresponding to an amount of change between the second and the first impedance measurement (e.g., three percent change, five percent change). In another example, the predetermined impedance threshold may correspond to a rate of change (e.g., slope, differential) determined from the first and second impedance measurements. The controller **251** may compare a difference or delta between the second impedance measurement (e.g., the impedance measurement **2754**) and the first impedance measurement (e.g., the impedance measurement **2752**) with the predetermined impedance threshold to determine whether the impedance has changed (e.g. increased, decreased) from the first impedance measurement to the second impedance measurement.

(137) For example, the controller **251** may select the impedance measurement **2752** and the impedance measurement **2754**. The controller **251** may calculate a difference **2770** of, for example a two percent drop, between the impedance measurements **2752-2754**. The controller **251** may compare the difference **2770** with the predetermined impedance threshold of, for example three percent. It should be noted that in other embodiments the predetermined impedance threshold may be greater than or less than three percent. If the magnitude of the difference **2770** is greater than the threshold, the controller **251** may determine that the impedance changed (e.g., increased, decreased) between the first and second impedance measurements. Alternatively, if the magnitude of the difference **2770** is lower than the threshold, the controller **251** may determine that the impedance did not change. For example, the controller **251** may determine that since the difference **2770** (e.g., a two percent) is below the predetermined impedance threshold (e.g., three percent) the impedance measurements did not change.

(138) Based on a determination that the impedance has not changed between impedance measurements, the controller **251** may determine that the substrate surrounding the lead **402** has not changed. For example, as indicated along row **2808** in the decision table **2800**, a substrate change is

shown based on a change in impedance. Since the controller **251** determined that the impedance measurements did not change, the controller **251** may determine that a substrate change surrounding the lead **402** has not occurred.

(139) The ECAP amplitude column **2804** corresponds to differences determined by the controller **251** between the first ECAP measurement (e.g., the peak to peak measurement **2764**) and the second ECAP measurement (e.g., the peak to peak measurement **2766**) selected at **2658** of FIG. **26**.

(140) For example, the controller **251** may determine whether the ECAP measurement increases, decreases, and/or does not change from the first ECAP measurement to the second ECAP measurement based on a predetermined ECAP amplitude threshold. The predetermined ECAP amplitude threshold may be stored in the memory **261**, and correspond to an amount of change between two ECAP measurements that can be determined and/or verified by the controller **251** as an increase and/or decrease in ECAP amplitude.

(141) For example, the predetermined ECAP amplitude threshold may correspond to an amount of change between the ECAP measurements that is greater than electrical noise (e.g., additive noise, electromagnetic interference, signal-to-noise ratio) generated by the operation of the IPG **250**. The predetermined ECAP amplitude threshold may be a percentage corresponding to an amount of change between the second and the first ECAP measurements (e.g., three percent change, five percent change). In another example, the predetermined ECAP amplitude threshold may correspond to a rate of change (e.g., slope, differential) determined from the first and the second ECAP measurements. The controller **251** may compare a difference or delta between the second ECAP (e.g., the peak to peak measurement **2766**) and the first ECAP measurement (e.g., the peak to peak measurement **2764**) with the predetermined ECAP amplitude threshold to determine whether the ECAP amplitude has changed from the first ECAP measurement to the second ECAP measurement.

(142) For example, the controller **251** may select the peak to peak measurement **2764** and the peak to peak measurement **2766**. The controller **251** may calculate a difference **2774** (e.g., at **2658** of FIG. **26**), for example a one and a half percent increase, between the ECAP measurements **2764-2766**. The controller **251** may compare the difference **2774** with the predetermined ECAP amplitude threshold of, for example of three percent. It should be noted that in other embodiments the predetermined ECAP amplitude threshold may be greater than or less than three percent. If the magnitude of the difference **2774** is greater than the threshold, the controller **251** may determine that the ECAP amplitude changed between the ECAP measurements. Alternatively, if the magnitude of the difference **2774** is lower than the threshold, the controller **251** may determine that the ECAP amplitude did not change. For example, the controller **251** may determine that since the difference **2774** (e.g., a one and a half percent increase) is below the predetermined ECAP amplitude threshold (e.g., three percent) the ECAP measurements did not change.

(143) Based on a determination that the ECAP amplitudes have not changed between ECAP measurements, the controller **251** may determine that the lead **402** has not moved relative to the SC tissue between the ECAP measurements and the SC tissue is not damaged. For example, as indicated along rows **2810**, **2812**, **2814**, **2816**, **2820**, and **2821** in the decision table **2800**, a movement in the lead **402** and damage to the SC tissue is shown based on a change in ECAP amplitude. Since the controller **251** determined that the ECAP measurements did not change, the controller **251** may determine that the lead **402** did not move between the ECAP measurements and/or the SC tissue is not damaged.

(144) In various embodiments, the controller **251** may compare the ECAP measurements to a critical threshold. The critical threshold may be stored in the memory **261**. The critical threshold may correspond to a change between the two ECAP measurements indicating neural tissue damage of the SC. The critical threshold is greater than the ECAP amplitude threshold. For example, the critical threshold may be a percentage corresponding to an amount of change between the first and the second ECAP measurement (e.g., thirty percent change, forty percent change, fifty percent

change). In another example, the predetermined ECAP amplitude threshold may correspond to a rate of change (e.g., slope, differential) determined from the first and second ECAP measurement. (145) FIG. 29 illustrates a flow chart of a method of a plurality of operations performed by the controller 251 at 2660 (FIG. 26) to detect damage to neural tissue of the SC, substrate change, and/or movement of the lead 402 described at 2660 of FIG. 26. The method is based on the decision table 2800.

(146) Beginning at 2902, the controller 251 determines whether the ECAP amplitude has decreased between the first ECAP measurement and the second ECAP measurement more than the critical threshold. For example, the controller 251 may select at 2656 (FIG. 26) the peak to peak measurement 2766 as the first ECAP measurement and the peak to peak measurement 2768 as the second ECAP measurement. It should be noted that the peak to peak measurements 2766-2768 are temporally separated from each other, resulting from different pulses 2706-2708, respectively, of the stimulation waveform 2702. At 2658 (FIG. 26), the controller 251 may compare the peak to peak measurements 2762-2764 to determine a difference 2724, for example a ten percent decrease, between the ECAP measurements. For example, the peak to peak measurement 2764 is ten percent lower than the peak to peak measurement 2762. The controller 251 may compare the difference 2724 with the predetermined critical threshold, for example of thirty percent. Since, the difference 2724 is lower than the critical threshold, the controller 251 may determine that no neural tissue damage of the SC due to over stimulation is detected.

(147) Alternatively, if the magnitude of the difference 2724 was greater than the critical threshold, the controller 251 may determine, at 2912, neural tissue damage of the SC at and/or proximate to the stimulation target due to overstimulation.

(148) At 2904, the controller 251 determines whether the ECAP amplitude has increased between the first ECAP measurement and the second ECAP measurement. The controller 251 may compare the difference 2776 determined at 2658 with the predetermined ECAP amplitude threshold to determine whether an increase of the ECAP measurement corresponds to lead 402 movement. For example, the difference 2776 corresponds to an increase in the second ECAP measurement (e.g., the peak to peak measurement 2768) of twenty percent. The controller 251 may compare the difference 2776 with the predetermined ECAP amplitude threshold of, for example, three percent. Since the difference 2776 is greater than the predetermined ECAP amplitude threshold, the controller 251 may determine that the ECAP amplitude increased.

(149) Alternatively, if the difference 2776 is lower than the predetermined ECAP amplitude threshold, the controller 251 may determine that the ECAP amplitude did not increase and that the lead 402 did not move towards the SC tissue and/or stimulation target.

(150) At 2913, the controller 251 determines whether the ECAP amplitude decreased above the critical threshold within a time period. The time period may be based on a number of subsequent pulses of the stimulation waveform 2702, relative to the peak to peak measurement used in 2904. For example, the time period may correspond to when the successive pulse 2712 occurs relative to the pulse 2710 which corresponds to the peak to peak measurement 2768. Additionally, or alternatively, the time period may be based on a number of a subsequent stimulation waveforms, relative to the peak to peak measurement used in 2904. In various embodiments, the time period may be based on time length, such as seconds, minutes, and/or hours.

(151) Optionally, a length of the time period may be based on a procedure being performed on the patient. For example, during implantation of the lead 210 into the patient, the controller 251 may have the time period be a short period (e.g., several seconds, less than minutes). When the implantation is complete, the controller 251 may have the time period be longer relative to the implantation procedure (e.g., several hours, days).

(152) After the time period, the controller 251 may determine whether the ECAP amplitude has decreased between the ECAP measurement used in 2904, the peak to peak measurement 2768, and a second ECAP measurement after the time period. For example, the time period may be based on

the subsequent pulse, the pulse **2712**. The controller **251** may select the corresponding peak to peak measurement **2770** as the second ECAP measurement. The controller **251** may compare the peak to peak measurements **2768-2770** to determine a difference **2778**, for example a thirty-five percent decrease, between the ECAP measurements (e.g., **2768-2770**). For example, the peak to peak measurement **2770** is thirty-five percent lower than the peak to peak measurement **2768**. The controller **251** may compare the difference **2778** with the predetermined critical threshold, for example of thirty percent. Since, the difference **2778** is lower than the critical threshold, the controller **251** may determine, at **2915**, that neural tissue damage of the SC due to pressure from the lead **402** is detected.

(153) Alternatively, if the controller **251** determines at **2913** that the ECAP amplitude did not decrease above the critical threshold after the time period, then at **2914**, the controller **251** may determine that the ECAP amplitude increase at **2904** is due to lead **402** movement toward the SC tissue.

(154) At **2906**, the controller **251** determines whether the ECAP amplitude has decreased. The controller **251** may compare a difference between the first ECAP measurement and the second ECAP measurement determined at **2658** with the predetermined ECAP amplitude threshold to determine whether a decrease from the first ECAP measurement to the second ECAP measurement corresponds to lead **402** moving away from the SC and/or stimulation. If the difference is greater than the predetermined ECAP amplitude threshold, the controller **251** at **2916** may determine that the ECAP amplitude decrease is due to lead **402** movement away from the SC tissue and/or stimulation target. Alternatively, if the difference is lower than the predetermined ECAP amplitude threshold, the controller **251** may determine that the lead **402** did not move away from the SC tissue and/or stimulation target.

(155) At **2908**, the controller **251** determines whether the impedance has changed (e.g., increased, decreased) between the first impedance measurement and the second impedance measurement above the predetermined impedance threshold. For example, the controller **251** may select at **2656** (FIG. **26**) the impedance measurement **2754** as the first impedance measurement and the impedance measurement **2756** as the second impedance measurement. It should be noted that the impedance measurements **2754-2756** are temporally separated from each other, resulting from different pulses **2706-2708**, respectively, of the stimulation waveform **2702**. At **2658** (FIG. **26**), the controller **251** may compare the impedance measurements **2754-2756** to determine a difference **2772**, for example a fifteen percent decrease, between the impedance measurements **2754-2756**. For example, the impedance measurement **2756** is fifteen percent lower than the impedance measurement **2754**. The controller **251** may compare the difference **2772** with the predetermined impedance threshold of, for example of five percent. If the magnitude of the difference **2772** is higher than the predetermined impedance threshold, at **2918**, the controller **251** may determine a substrate change proximate to the lead **402**. If the magnitude of the difference **2772** is below and/or lower than the predetermined impedance threshold, the controller **251** may determine, at **2910**, that no neural tissue damage, lead **402** movement, or substrate change is detected.

(156) Returning to FIG. **26**, if the controller **251** detects damage to the SC tissue, a substrate change, or movement of the lead, at **2662**, the controller **251** may adjust at least one stimulation parameter of the stimulation waveform **2702** or may indicate a need to re-position the lead **402**. The stimulation parameter of the stimulation waveform **2702** may correspond to an amplitude, frequency, number of pulses, and/or the like of the stimulation waveform **2702**. One or more of the stimulation parameters may be adjusted by the controller **251** based on the detection (e.g., damage of the SC tissue **2912**, lead **402** movement towards the SC tissue **2914**, lead **402** movement away from the SC tissue **2916**, a substrate change proximate to the lead **2918**) at **2660**.

(157) For example, if the controller **251** detects the lead **402** has moved away from the SC tissue and/or stimulation target, the controller **251** may increase the amplitude of the pulses **2704-2712** forming the stimulation waveform **2702**, increase the duration of pulses **2704-2712** of the

stimulation waveform **2702**, increase the number of pulses **2704-2712** forming the stimulation waveform **2702**, and/or the like.

(158) In another example, if the controller **251** detects the lead **402** has moved towards the SC tissue, the controller **251** may decrease the amplitude of the pulses **2704-2712** forming the stimulation waveform **2702**, decrease the duration of pulses **2704-2712** of the stimulation waveform **2702**, decrease the number of pulses **2704-2712** forming the stimulation waveform **2702**, and/or the like.

(159) Optionally, the controller **251** may have the IPG **250** stop delivering the stimulation waveform **2702**. For example, if the controller **251** detects SC tissue damage, the controller **251** may have the IPG **250** stop delivering pulses **2704-2712** forming the stimulation waveform **2702** to the electrodes **511**.

(160) Additionally, or alternatively, the controller **251** may transmit to an external device, such as the system **100**, via the far-field and/or near field communication circuitry **255** when the controller **251** detects damage to the SC tissue, a substrate change, or movement of the lead, at **2662**. For example, the controller **251** may transmit an alert signal to the system **100** when the substrate proximate to the lead **402** has changed and/or neural damage of the SC tissue is detected.

(161) The controller **251**, the CPU **102**, and the CPU **152** may include any processor-based or microprocessor-based system including systems using microcontrollers, reduced instruction set computers (RISC), application specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), logic circuits, and any other circuit or processor capable of executing the functions described herein. Additionally, or alternatively, the controller **251**, the CPU **102**, and the CPU **152** may represent circuit modules that may be implemented as hardware with associated instructions (for example, software stored in a tangible and non-transitory computer readable storage medium, such as a computer hard drive, ROM, RAM, or the like) that perform the operations described herein. The above examples are exemplary only, and are thus not intended to limit in any way the definition and/or meaning of the term “controller.” The controller **251**, the CPU **102**, and the CPU **152** may execute a set of instructions that are stored in one or more storage elements, in order to process data. The storage elements may also store data or other information as desired or needed. The storage element may be in the form of an information source or a physical memory element within the controller **251**, the CPU **102**, and the CPU **152**. The set of instructions may include various commands that instruct the controller **251**, the CPU **102**, and the CPU **152** to perform specific operations such as the methods and processes of the various embodiments of the subject matter described herein. The set of instructions may be in the form of a software program. The software may be in various forms such as system software or application software. Further, the software may be in the form of a collection of separate programs or modules, a program module within a larger program or a portion of a program module. The software also may include modular programming in the form of object-oriented programming. The processing of input data by the processing machine may be in response to user commands, or in response to results of previous processing, or in response to a request made by another processing machine.

(162) It is to be understood that the subject matter described herein is not limited in its application to the details of construction and the arrangement of components set forth in the description herein or illustrated in the drawings hereof. The subject matter described herein is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

(163) It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments (and/or aspects thereof) may be used in combination with each other. In addition, many modifications may be made to adapt a particular

situation or material to the teachings of the invention without departing from its scope. While the dimensions, types of materials and coatings described herein are intended to define the parameters of the invention, they are by no means limiting and are exemplary embodiments. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects. Further, the limitations of the following claims are not written in means—plus-function format and are not intended to be interpreted based on 35 U.S.C. § 112(f), unless and until such claim limitations expressly use the phrase “means for” followed by a statement of function void of further structure.

Claims

1. A method for detecting spinal cord tissue damage, comprising: applying electrical pulses from at least one electrode of a lead, wherein the lead is positioned proximate to spinal cord (SC) tissue; obtaining impedance measurements; obtaining evoked compound action potential (ECAP) measurements generated in response to the electrical pulses; determining an ECAP difference based on the ECAP measurements; determining an impedance difference based on the impedance measurements; distinguishing between at least two of i) SC tissue damage, ii) movement of the lead and iii) substrate change, based on predetermined combinations of the ECAP difference and the impedance difference; and adjusting at least one stimulation parameter to change the electrical pulses based on the distinguishing operation.
2. The method of claim 1, wherein the distinguishing distinguishes between i) the SC tissue damage and ii) the movement of the lead, relative to the SC tissue, based on the predetermined combination of the ECAP difference and the impedance difference.
3. The method of claim 1, wherein the distinguishing distinguishes between i) the SC tissue damage and ii) the substrate change based on the predetermined combination of the ECAP difference and the impedance difference, wherein the substrate change represents a change in a composition of SC tissue proximate spinal fluid.
4. The method of claim 1, further comprising detecting a direction of the movement of the lead, relative to the SC tissue, based on the predetermined combination of the ECAP difference and the impedance difference.
5. The method of claim 1, further comprising detecting a direction of the movement of the lead, relative to the SC tissue, in accordance with at least one of the following: a) lead movement away from the SC tissue when a second ECAP measurement decreases relative to a first ECAP measurement and a second impedance measurement increases relative to a first impedance measurement; b) lead movement away from the SC tissue when the second ECAP measurement decreases relative to the first ECAP measurement and the first and second impedance measurements are the same; c) lead movement toward the SC tissue when the second ECAP measurement increases relative to the first ECAP measurement and the second impedance measurement decreases relative to the first impedance measurement; or d) lead movement toward the SC tissue when the second ECAP measurement increases relative to the first ECAP measurement and the first and second impedance measurements are the same.
6. The method of claim 1, further comprising determining that the SC tissue damage is due to overstimulation or pressure from the lead based on a decrease or increase, respectively, in the ECAP difference.
7. The method of claim 1, further comprises determining that the SC tissue damage is due to

overstimulation based on no change in the impedance difference.

8. A system for detecting spinal cord (SC) tissue damage comprising: an implantable pulse generator (IPG) in communication with a lead configured to be positioned proximate to spinal cord (SC) tissue, the lead including at least one electrode configured to apply electrical pulses; sensing circuitry configured to sense evoked compound action potential (ECAP) signals generated in response to the electrical pulses; a memory device configured to store programmed instructions; and a processor that, when executing the programmed instructions, is configured to: obtain impedance measurements; obtain ECAP measurements from the ECAP signals; determine an ECAP difference based on the ECAP measurements; determine an impedance difference based on the impedance measurements; and distinguish between at least two of i) SC tissue damage, ii) movement of the lead and iii) substrate change, based on predetermined combinations of the ECAP difference and the impedance difference; and adjust at least one stimulation parameter to change the electrical pulses based on the distinguishing operation.

9. The system of claim 8, wherein the processor is further configured to distinguish between i) the SC tissue damage and ii) the movement of the lead, relative to the SC tissue, based on the predetermined combination of the ECAP difference and the impedance difference.

10. The system of claim 8, wherein the processor is further configured to distinguish between i) the SC tissue damage and ii) the substrate change based on the predetermined combination of the ECAP difference and the impedance difference, wherein the substrate change represents a change in a composition of SC tissue proximate the spinal fluid.

11. The system of claim 8, wherein the processor is further configured to detect a direction of the movement of the lead, relative to the SC tissue, based on the predetermined combination of the ECAP difference and the impedance difference.

12. The system of claim 8, wherein the processor is further configured to detect a direction of the movement of the lead, relative to the SC tissue, in accordance with at least one of the following: a) lead movement away from the SC tissue when a second ECAP measurement decreases relative to a first ECAP measurement and a second impedance measurement increases relative to a first impedance measurement; b) lead movement away from the SC tissue when the second ECAP measurement decreases relative to the first ECAP measurement and the first and second impedance measurements are the same; c) lead movement toward the SC tissue when the second ECAP measurement increases relative to the first ECAP measurement and the second impedance measurement decreases relative to the first impedance measurement; or d) lead movement toward the SC tissue when the second ECAP measurement increases relative to the first ECAP measurement and the first and second impedance measurements are the same.

13. The system of claim 8, wherein the processor is further configured to determine that the SC tissue damage is due to overstimulation or pressure from the lead based on a decrease or increase, respectively, in the ECAP difference.

14. The system of claim 8, wherein the processor is further configured to determine that the SC tissue damage is due to overstimulation based on no change in the impedance difference.
